


Description

Background of the invention

This invention relates to the total synthesis of certain 1-carbapenems and their pharmaceutically acceptable salt, ester and amide derivatives which are useful as antibiotics. Such compounds may generically be represented by the following structural formula:



wherein R⁶ and R⁷, are independently selected from the group consisting of hydrogen, substituted and unsubstituted: alkyl, alkenyl, and alkynyl, having from 1—10 carbon atoms; cycloalkyl, cycloalkylalkyl, and alkylcycloalkyl, having 3—6 carbon atoms in the cycloalkyl ring and 1—6 carbon atoms in the alkyl moieties; phenyl; aralkyl, aralkenyl, and aralkynyl wherein the aryl moiety is phenyl and the aliphatic portion has 1—6 carbon atoms; wherein the substituent or substituents relative to the above-named radicals are selected from the group consisting of:

—X^o halo (chloro, bromo, fluoro) and R¹

—OH hydroxy


—OR¹ alkoxy, aryloxy

 —OCNR¹R² carbamoyloxy

 —CNR¹R² carbamoyl

—NR¹R² amino

—NH₂, —NHR¹

 amidino

—SO₂NR¹R² sulfonamido

 —NHCNR¹R² ureido

 R¹CNR²— amido

5 $-\text{CO}_2\text{H}$ carboxy

10 $-\text{CO}_2\text{R}^1$ carboxylate

15 $\begin{array}{c} \text{O} \\ \parallel \\ -\text{CR}^1 \end{array}$ acyl

20 $\begin{array}{c} \text{O} \\ \parallel \\ -\text{OCR}^1 \end{array}$ acyloxy

25 $-\text{SH}$ mercapto

30 $\begin{array}{c} \text{O} \\ \parallel \\ -\text{SR}^1 \end{array}$ alkyl and aryl sulfinyl

35 $\begin{array}{c} \text{O} \\ \parallel \\ -\text{SR}^1 \end{array}$ alkyl and aryl sulfonyl

40 $\begin{array}{c} \text{O} \\ \parallel \\ -\text{CN} \end{array}$ cyano

45 $-\text{N}_3$ azido

45 wherein, relative to the above listed substituents on R^6 and R^7 , the groups R^1 and R^2 are independently selected from: hydrogen, alkyl, alkenyl, and alkynyl, having from 1—10 carbon atoms; cycloalkyl, cycloalkylalkyl, and alkylcycloalkyl, having 3—6 carbon atoms in the cycloalkyl ring and 1—6 carbon atoms in the alkyl moieties; phenyl; aralkyl, aralkenyl, and aralkynyl wherein the aryl moiety is phenyl and the aliphatic portion has 1—6 carbon atoms; R^6 and R^7 are not both hydrogen at the same time; when R^6/R^7 is hydrogen, then R^7/R^6 is not

55



or



60

60 R^8 is selected from hydrogen, substituted and unsubstituted: alkyl, alkenyl, and alkynyl, having from 1—10 carbon atoms; cycloalkyl, cycloalkylalkyl, and alkylcycloalkyl, having 3—6 carbon atoms in the cycloalkyl ring and 1—6 carbon atoms in the alkyl moieties; phenyl; aralkyl, aralkenyl, and aralkynyl wherein the aryl moiety is phenyl and the aliphatic portion has 1—6 carbon atoms; heteroaryl, heteroaralkyl, heterocyclyl and heterocyclylalkyl wherein the heteroaryl moiety or the heterocyclyl moiety has 5 or 6 ring members

0037 082

containing 1—4 O, N and S atoms and the alkyl moieties have 1 to 6 carbon atoms; wherein the substituent or substituents relative to the above-named radicals are selected from the group consisting of:

5 $-X^{\circ}$ halo (chloro, bromo, fluoro)

$-OH$ hydroxy

$-OR^1$ alkoxy, aryloxy

10

$\begin{array}{c} O \\ || \\ -OCNR^1R^2 \end{array}$ carbamoyloxy

15

$\begin{array}{c} O \\ || \\ -CNR^1R^2 \end{array}$ carbamoyl

20

$-NR^1R^2$ amino

25

$\begin{array}{c} NR^1 \\ \diagup \\ \diagdown \\ NR^1R^2 \end{array}$ amidino

$-SO_2NR^1R^2$ sulfonamido

30

$\begin{array}{c} O \\ || \\ -NHCNR^1R^2 \end{array}$ ureido

35

$\begin{array}{c} O \\ || \\ R^1CNR^2 \end{array}$ amido

$-CO_2H$ carboxy

40

$-CO_2R^1$ carboxylate

45

$\begin{array}{c} O \\ || \\ -CR^1 \end{array}$ acyl

$\begin{array}{c} O \\ || \\ -OCR^1 \end{array}$ acyloxy

50

$-SH$ mercapto

55

$\begin{array}{c} O \\ || \\ -SR^1 \end{array}$ alkyl and aryl sulfinyl

60

$\begin{array}{c} O \\ || \\ -SR^1 \\ || \\ O \end{array}$ alkyl and aryl sulfonyl


65

$-CN$ cyano

$-N_3$ azido





wherein, relative to the above listed substituents on R^6 , the groups R^1 and R^2 are independently selected from: hydrogen, alkyl, alkenyl, and alkynyl, having from 1—10 carbon atoms; cycloalkyl, cycloalkylalkyl, and alkylcycloalkyl, having 3—6 carbon atoms in the cycloalkyl ring and 1—6 carbon atoms in the alkyl moieties; phenyl; aralkyl, aralkenyl, and aralkynyl wherein the aryl moiety is phenyl and the aliphatic portion has 1—6 carbon atoms; heteroaryl, heteroaralkyl, heterocyclyl and heterocyclylalkyl wherein the heteroaryl moiety or the heterocyclyl moiety has 5 or 6 ring members containing 1—4 oxygen, nitrogen or sulphur atoms and wherein the alkyl moieties associated with said heterocyclic moieties have 1—6 carbon atoms.

This invention also relates to the carboxyl derivatives of I which are antibiotics and which may be represented by the following generic structure (I):




wherein X' is oxygen or NR' ($R' = H$ or lower alkyl having 1—6 carbon atoms); and R^3' is, representatively selected from the group consisting of hydrogen, conventional blocking groups such as trialkylsilyl, acyl and the pharmaceutically acceptable salt, ester and amide moieties known in the bicyclic β -lactam antibiotic art; the definition of R^3' is given in greater detail below.

Starting from L-aspartic acid, the synthesis proceeds *via* intermediates II, III, IV and V:



wherein R^6 and R^7 are as previously defined; R^e is hydrogen or a readily removable known protecting group; X is a conventional leaving group and R^2' is hydrogen, a pharmaceutically acceptable ester moiety or a conventional, readily removable protecting group or salt cation. For intermediates IV, R^2' is as defined but preferably is an ester moiety defined under R^2' ; R^1' is hydrogen or a readily removable known protecting group such as a triorganosilyl group; R^a and R^b are independently selected from alkyl having 1—6 carbon atoms, such as methyl, ethyl or phenyl, trityl, benzyl, methoxybenzyl, ethoxybenzyl; additionally, R^a and R^b may be joined together, to form $-(CH_2)_3-$ to bridge the two sulphur atoms; R^c is alkyl having 1—6 carbon atoms, such as methyl, ethyl or phenyl. The details of the total synthesis are given below.

The invention also relates to intermediates having the structure



wherein $R^{1'}$ is hydrogen or a readily removable known protecting group; R^a and R^b are independently selected from: alkyl having 1—6 carbon atoms, phenyl, trityl, benzyl, methoxybenzyl, ethoxybenzyl and $-(CH_2)_3-$ (joinder of R^a and R^b); R^c is alkyl having 1—6 carbon atoms, or phenyl; and wherein R^6 and R^7 are independently selected from the group consisting of: hydrogen; substituted and unsubstituted: alkyl, alkenyl, and alkynyl, having from 1—10 carbon atoms; cycloalkyl, cycloalkylalkyl, and alkylcycloalkyl having 3—6 carbon atoms in the cycloalkyl ring and 1—6 carbon atoms in the alkyl moieties; phenyl; aralkyl, aralkenyl, and aralkynyl wherein the aryl moiety is phenyl and the aliphatic portion has 1—6 carbon atoms; wherein the substituent or substituents relative to the above named radicals are selected from the group consisting of:

chloro, bromo, fluoro, R^1 ,

chloro, bromo, fluoro, R^1 ,

$-OH$,

$-OR^1$,

$-OC(=O)NR^1R^2$,

$-C(=O)NR^1R^2$,

$-NR^1R^2$,

$-NH_2$,






$-NHR^1$,

$-C(=NR^1)(NR^1R^2)-$,

$-SO_2NR^1R^2$,

$-NH-C(=O)NR^1R^2$,

$-R^1-C(=O)NR^1$,



wherein, relative to the above listed substituents on R^6 , and R^7 , the groups R^1 and R^2 are independently selected from: hydrogen, alkyl, alkenyl, and alkynyl, having from 1—10 carbon atoms; cycloalkyl, cycloalkylalkyl, and alkylcycloalkyl, having 3—6 carbon atoms in the cycloalkyl ring and 1—6 carbon atoms in the alkyl moieties; phenyl, aralkyl, aralkenyl, and aralkynyl wherein the aryl moiety is phenyl and the aliphatic portion has 1—6 carbon atoms; R^6 and R^7 are not both hydrogen at the same time; when R^6/R^7 is hydrogen, then R^7/R^6 is not



or




The final compounds, prepared by the process of this invention are disclosed and claimed in the following copending, European Patent Application 78,101,156.

Thus, it is an object of the present invention to provide a novel class of antibiotics which are useful in animal and human therapy and in inanimate systems. These antibiotics are active against a broad range of pathogens which representatively include both gram positive bacteria such as *S. aureus*, *Strep. pyogenes*, and *B. subtilis*, and gram negative bacteria such as *E. coli*, *Pseudomonas*, *Proteus morganii*, *Serratia*, and *Klebsiella*. Further objects of this invention are to provide chemical processes for the preparation of such antibiotics and their non-toxic pharmaceutically acceptable salts and pharmaceutical compositions comprising such antibiotics.


Detailed Description of the Invention

The process of the present invention may conveniently be summarized by the following reaction diagram:


DIAGRAM I




1




2




3



4




5



6


DIAGRAM I (continued)

5




10

15




20

25




30

35




40

45



50


55




60

65


DIAGRAM I (continued)




13




14




15




16



17



18




1

In words relative to the above diagram, L-aspartic acid 1 is esterified according to well known procedures. Typically 1 in a solvent such as benzene, toluene or chloroform is treated with an esterifying agent such as benzyl alcohol, methanol, ethanol or isopropanol, in the presence of p-toluene sulfonic acid, HCl, HBr, for example at a temperature of from 0° to 110°C for from 1 to 24 hours to achieve the desired establishment and hence protection of the carboxyl functions. Thus, R^a is any convenient carboxyl protecting group such as benzyl, methyl, ethyl or isopropyl. The resulting species 2 in a solvent such as ether, THF or DME is treated with trimethylchlorosilane, for example, followed by treatment with EtMgBr, MeMgI, ϕ MgBr, t-BuMgCl, for example at a temperature of from -40 to 50°C for from 1 to 72 hours to provide azetidinone 3. Reduction of species 3 with a reducing agent such as NaBH₄, in a solvent such as methanol, ethanol or isopropanol at a temperature of from -10 to 40°C for from 1 to 6 hours provides 4. (For purposes here, the symbols: Et, Me, ϕ , iPr, and t-Bu stand for: ethyl, methyl, phenyl, isopropyl, and tert-butyl, respectively.)

Treatment of 4 in solvent such as methylene chloride or CHCl₃ with methane sulfonyl chloride, methane sulfonic anhydride for example in the presence of a base such as Et₃N or iPr₂NEt, followed by treatment with a stoichiometric to 5-fold excess of sodium iodide in acetone yields 6 *via* 5.

The transformation 6 → 7 establishes the protecting group R¹ which may be a triorganosilyl group, such as t-butyldimethylsilyl, t-butyldiphenylsilyl, triphenylsilyl, isopropyldimethylsilyl, or may be 3,4-dimethoxybenzyl, for example. Silyl protection is preferred, and typically R¹ is established by treating 6 in a solvent such as dimethylformamide, acetonitrile, hexamethylphosphoramide or tetrahydrofuran with a silylating agent such as t-butyldimethylchlorosilane, t-butyldiphenylchlorosilane or triphenylchlorosilane, at a temperature of from -20°C to 25°C for from 0.5 to 24 hours in the presence of a base such as triethylamine diisopropylethylamine or imidazole.

The transformation 7 → 8 is accomplished by treating 7 in a solvent such as tetrahydrofuran, dimethoxyethane or diethylether with a carbanion generically represented by the following structure:



wherein M is a metal cation such as lithium, potassium copper or magnesium, for example, and R^a, R^b and R^c are as defined above at a temperature of from -100 to 0°C and from 0.5 to 4 hours.

Typically, the carbanion reagent is prepared prior to addition of substrate 7 on treatment of the di-organothiomonoorganosilylmethane with a strong base such as n-butyl-lithium, t-butyllithium, phenyllithium or lithium diisopropylamide (LDA).

Resulting intermediate 8 can be mono-, or dialkylated at ring position 3. Alkylation of 8 provides 9. Typically, 8 is treated with a strong base such as lithium diisopropylamide, lithium 2,2,6,6-tetramethylpiperidide, potassium hydride, lithium hexamethyldisilazane or phenyllithium in a solvent such as tetrahydrofuran (THF), hexamethylphosphoramide, ether or dimethoxyethane, at a temperature of from -80°C to 0°C whereupon the alkylating agent of choice, R⁶X^o is added (X^o is chloro, iodo or bromo); alternatively the alkylating agent may be R⁶-tosylate, R⁶-mesylate or an aldehyde or ketone such as azcetaldehyde to provide monoalkylated species 9. When desired, dialkylated species 10 may be obtained from 9 by repeating the alkylating procedures 8 → 9.

The eventual 6-substituents (nomenclature relative to final, bicyclic structure) can also be established by direct acylation using an acylating agent such as N-acyl imidazole. Such N-acyl imidazole acylating reagents are listed below. Also given below is a detailed description of this second approach for establishing, R⁶ and R⁷.

The following list is representative of useful *alkylating* agents for establishing R⁶ and R⁷, according to the above scheme: 8 → 9 → 10 (this will be referred to as Scheme I, to be distinguished from Scheme II, below, which involves *acylation*):

19


0037082

ALKYLATING AGENTS

5



10




ϕ = phenyl



15



20




25



30




35





40



45



50



55



60



R = CH_3 , benzyl, p-nitrobenzyl

65



23

0037082

ALKYLATING AGENTS (continued)

5




R = CH₃, benzyl, p-nitrobenzyl

10





15




20



25




30





35




40




45



50




55




R = protecting group

60



65 R is a removable known carboxyl protecting group, such as benzyl.


As mentioned above, the 6-substituents may also be established by acylation. Utilization of such acylating agents may be demonstrated in the following manner with regard to a preferred starting, or intermediate material 10:



9 or 10

wherein R^7 and $R^{1'}$ are as defined above. R^6 is defined relative to the definition of R^6 and in that sense is the balance of the previously identified group R^6 . In other words, for purposes of this definition $R^6CH(OH) = R^6$. An especially preferred material 10 is when R^7 is hydrogen and R^6 is methyl. Basically, such 1'-hydroxy R^6 species 10 are prepared according to the following scheme:

SCHEME II






The alkylation $8 \rightarrow 9$, Scheme II, is accomplished as previously described, by treating 8 in a solvent such as tetrahydrofuran, dimethoxyethane, diethylether, hexamethylphosphoramide, at a temperature of from -100° to -20°C with a strong base such as lithium diisopropylamide, lithium hexamethyldisilazide, lithium 2,2,6,6-tetramethylpiperidide or potassium hydride followed by the addition of an equivalent to 10 fold excess of an aldehyde. This reaction gives a mixture of isomers from which the desired *trans*-R form 9 (or 10) can be conveniently separated by chromatography or crystallization.

Intermediate 8 may proceed directly to 9 as indicated above, or it may take the circuitous path via 9'. The direct acylation, to 9' is accomplished by treating 8 with two or more equivalents of a base such as lithium diisopropylamide, lithium hexamethyldisilazide, lithium 2,2,6,6-tetramethylpiperidide, in a solvent such as tetrahydrofuran, diethylether, or dimethoxyethane, for example, at a temperature of from -100 to -20°C with an acylating agent such as N-acyl imidazole. Addition of the 8 plus base mixture to the acylating agent is preferred.

0037082


Representative acylating agents for this scheme 8 → 9' → 9 are listed below.



20

Further with respect to Scheme II, the reduction, 8' → 9 is accomplished by contacting the ketone with a reducing agent such as potassium tri(sec-butyl)borohydride, lithium tri(sec-butyl)borohydride, sodium borohydride, sodium tris(methoxyethoxy)aluminium hydride or lithium aluminium hydride in a solvent such as diethylether, tetrahydrofuran or toluene at a temperature of from -78° to 25°C. The reaction can conveniently be conducted in the presence of an added complexing salt such as potassium iodide or magnesium bromide.

In a similar manner, unresolved 9 (*cis* and *trans*) may be oxidized to 9' for reduction to 9 as indicated above:



40

The oxidation is accomplished with an oxidizing agent such as dipyridine chromium (VI) oxide, trifluoroacetic anhydride-dimethylsulfoxide-triethylamine, pyridinium dichromate, acetic anhydride-dimethylsulfoxide in a solvent such as methylene chloride or acetonitrile, at a temperature of from -78 to 25°C for from 5 minutes to 5 hours.

Now return to the main course of reaction, DIAGRAM I, and the transformation 10 → 11. The transformation is accomplished by treating 10 in a solvent such as methanol, ethanol, isopropanol or water at a temperature of from 0 to 80°C with a Lewis acid such as mercuric chloride, silver tetrafluoroborate or thallium trinitrate.

The oxidation 11 → 12 is preferably achieved with a 1.0 to 5.0 fold excess of an oxidizing agent such as *m*-chloroperbenzoic acid, peracetic acid, hydrogen peroxide or pertrifluoroacetic acid, in a solvent such as chloroform, carbontetrachloride or chlorobenzene, at a temperature of from 25°C to 130°C for from 0.5 to 24 hours.

The addition 12 → 13 is accomplished by treating 12 with 1,1'-carbonyldimidazole, for example, in a solvent such as tetrahydrofuran, dimethoxyethane or DMF, at a temperature of from 0 to 50°C, followed by the addition of 0.5 to 3.0 equivalents of $(\text{R}^2\text{O}_2\text{CCH}_2\text{CO}_2)_2\text{Mg}$, at a temperature of from 0 to 50°C for from 1 to 48 hours. R^2 is a readily removable carboxyl protecting group such as *p*-nitrobenzyl or benzyl. It should also be noted that R^2 may be a pharmaceutically acceptable ester moiety; such ester groups are representatively mentioned below. (DMF is dimethylformamide.)

Removal of protecting group R^1 (13 → 14) may be accomplished by a variety of known procedures such as hydrolysis or hydrogenation. When R^1 is a triorganosilyl group (for example, $[(\text{CH}_3)_3\text{C}] (\text{CH}_3)_2\text{Si}-$) removal is typically accomplished by acidic aqueous hydrolysis of 13 in a solvent such as methanol, ethanol, tetrahydrofuran, dioxane or DMF, in the presence of an acid such as hydrochloric or sulfuric, acetic at a temperature of from 0 to 100°C for from 2 to 18 hours.

It should be noted that an otherwise identical deblocking can occur at level 10, 11, or 12. Thus, when $\text{R}^1 = \text{H}$, the chain elongation can proceed directly from 12 to 14.

The diazo species 15 is prepared from 14 by treating 14 in a solvent such as CH_3CN , CH_2Cl_2 or THF, with an azide such as p-carboxybenzenesulfonylazide, toluenesulfonylazide nor methanesulfonylazide, in the presence of a base such as triethylamine, pyridine or $(\text{C}_2\text{H}_5)_3\text{NH}$, for from 1 to 50 hours at $0-25^\circ\text{C}$. (THF is tetrahydrofuran.)

Cyclization (15 $\rightarrow$ 16) is accomplished by treating 15 in a solvent such as benzene, toluene or THF, at a temperature of from $50-110^\circ\text{C}$ for from 1-5 hours in the presence of a catalyst such as *bis* (acetylacetonato)Cu(II) [$\text{Cu}(\text{acac})_2$], CuSO_4 , Cu powder, $\text{Rh}(\text{OAc})_2$, or $\text{Pd}(\text{OAc})_2$. Alternatively, the cyclization may be accomplished by irradiating 15 through a pyrex filter (a wave length greater than 300 nm) in a solvent such as benzene, CCl_4 , or diethylether at a temperature of from $0-25^\circ\text{C}$ for from 0.5 to 2 hours.

["OAc" = acetate,]

Establishment of leaving group X (16 $\rightarrow$ 17) is accomplished by acylating the keto ester 16 with a known acylating agent R^0X such as p-toluenesulfonic acid anhydride, p-nitrophenylsulfonic acid anhydride, 2,4,6-triisopropylphenylsulfonic acid anhydride, methanesulfonic acid anhydride, trifluoromethane sulfonic acid anhydride, diphenyl chlorophosphate, toluenesulfonyl chloride or p-bromophenylsulfonyl chloride; wherein X is the corresponding leaving group such as toluene sulfonyloxy, p-nitrophenylsulfonyloxy, diphenylphosphoryl, and other leaving groups which are established by conventional procedures and are well known in the art. Typically, the above acylation to establish leaving groups X is conducted in a solvent such as methylene chloride, acetonitrile or dimethylformamide, in the presence of a base such as diisopropylethylamine, triethylamine or 4-dimethylamino-pyridine at a temperature of from -20 to 40°C for from 0.1 to 5 hours. The leaving group X of intermediate 17 can also be halogen. The halogen leaving group is established by treating 17 with a halogenating agent such as O_3PCl_2 , O_3PBr_2 , $(\text{O}_3\text{P})_2\text{Br}_2$ or oxalyl chloride in a solvent such as CH_2Cl_2 , CH_3CN or THF, in the presence of a base such as diisopropylethylamine, triethylamine, or 4-dimethylaminopyridine. [O - phenyl.]

The reaction 17 $\rightarrow$ 18 is accomplished by treating 17 in a solvent such as dioxane, dimethylformamide, dimethylsulfoxide, acetonitrile or hexamethylphosphoramide, in the presence of an approximately equivalent to excess of the mercaptan reagent HSR^8 , wherein R^8 is as defined above, in the presence of a base such as sodium hydrogen carbonate, potassium carbonate, triethylamine or diisopropylethylamine, at a temperature of from -40 to 25°C for from 1 to 72 hours. When R^8 is substituted by a primary or secondary amino group, for example $-\text{CH}_2\text{CH}_2\text{NH}_2$, the mercaptan reagent may be represented as $\text{HSCH}_2\text{CH}_2\text{NHR}^8$, for example; wherein R^8 is a readily removable known N-protecting group such as p-nitrobenzyloxycarbonyl, $(-\text{CO}_2\text{PNB})$ or o-nitrobenzyloxycarbonyl. The specifically illustrated mercaptan reagent, $\text{HSCH}_2\text{CH}_2\text{NHR}^8$, is typically prepared by treating the aminoethylmercaptan in the presence of the desired acid chloride in the presence of a base such as sodium bicarbonate or sodium hydroxide, in a solvent such as aqueous diethylether, aqueous dioxane or aqueous acetone, at a temperature of from 0 to 25°C for from 0.5 to 4 hours. The foregoing mercaptan reagent, HSR^8 , and means for its protection, is simply illustrative. The class of suitable HSR^8 reagents is representatively described below and in the Examples.

The final deblocking step 18 $\rightarrow$ I is accomplished by conventional procedures such as solvolysis or hydrogenation. Typically 18 in a solvent such as dioxane-water-ethanol or tetrahydrofuran-aqueous dipotassium hydrogen phosphate-isopropanol is treated under a hydrogen pressure of from 1 to 4 atmospheres in the presence of a hydrogenation catalyst such as palladium on charcoal, palladium hydroxide or platinum oxide, at a temperature of from 0 to 50°C for from 0.25 to 4 hours to provide I. Photolysis, when R^2 is a group such as o-nitrobenzyl, for example, may also be used for deblocking.

Introduction of the Thia Side Chain



Relative to the foregoing description of the invention, suitable reagents HSR^8 utilized in the transformation 17 $\rightarrow$ 18 are listed below. The list is arranged according to structural and functional characteristics of the thia side chain $-\text{SR}^8$; annotation is provided where necessary. The thia side chain of choice is derived from the corresponding mercaptan reagent HSR^8 . When the mercaptan contains a functional group which might interfere with the intended course of reaction, the offending group is covered. For example, when a basic nitrogen group is encountered ($-\text{NHR}$ or $-\text{NH}_2$, for example) it is usually protected by acylation (e.g., $-\text{CO}_2\text{PNB}$) and when a carboxyl group ($-\text{CO}_2\text{H}$) is present, it is usually protected by esterification (e.g., PNB ester). Such protection also facilitates in the purification of products 18 by chromatographic means. (PNB is p-nitrobenzyl).


1.) *Aliphatic Mercaptans*: HSR^* wherein R^* is 1—10 carbon alkyl, cycloalkyl, alkenyl, cycloalkenyl, or alkynyl; R^* may be branched or unbranched,

EXAMPLES


5




10




15




20




25



30




35




40




45







50




55



60







65















0037082

2.) *Substituted Aliphatic Mercaptans*: HSR^6 wherein R^6 is a 1—10 carbon branched or unbranched alkyl, cycloalkyl, alkenyl, cycloalkenyl or alkynyl group substituted by one or more halo,




wherein R^1 and R^2 are as previously defined relative to substituents on R^6 . Preferred substituents are basic nitrogen containing groups.

EXAMPLES




EXAMPLES (continued)


5




10





15




20



25




30




35

40




n = 3-5


45



50




55








60






65



EXAMPLES (continued)




$n = 1-3, R^2 = \text{H}, \text{CH}_3, R^1 = \text{H}, \text{CH}_3$




55

EXAMPLES (continued)

5




10




15

20




25



30


5-thio-D-glucose

35




40


45




50












55




60



65

EXAMPLES (continued)

3.) *Aryl Mercaptans*: HSR^8 wherein R^8 is phenyl or substituted phenyl. The substituents are independently selected from those previously defined for R^8 . Especially preferred substituents include alkyl, halo, hydroxy, alkoxy, acyloxy, acyl, carboxy, mercapto, sulfinyl, sulfonyl, amino, substituted amino, aminoalkyl, substituted aminoalkyl, amido, and ureido.



$n = 1, 2 \text{ or } 3,$

$\text{X} = \text{F}, \text{Cl}, \text{Br}, \text{OH}, \text{OR}, \text{OCR}^1, \text{NH}_2,$









$\text{NHR}^1, \text{NR}^1\text{R}^2, \text{CH}_2\text{NH}_2, \text{CH}_2\text{NR}^1\text{R}^2, \text{CO}_2\text{H},$

$\text{CO}_2\text{R}^1, \text{COR}^1, \text{CONH}_2, \text{CONR}^1\text{R}^2, \text{R}^1\text{CONH},$

$\text{R}^1\text{NHCONH}, \text{SR}^1, \text{SR}^1, \text{SO}_2\text{R}^1, \text{CH}_3, \text{CF}_3;$




R^1 and R^2 are as previously defined under R^8 .

EXAMPLES








4.) *Heteroaryl Mercaptans*: HSR^a wherein R^a is a substituted or unsubstituted heteroaryl group containing 1-4 O, N or S atoms. Typical substituents include those mentioned above under "Aryl Mercaptans".



EXAMPLES






$\text{X} = \text{N}, \text{O}$ $\text{Y} = \text{H}$
 $\text{X} = \text{S}$ $\text{Y} = \text{H}, \text{Cl}, \text{OCH}_2\text{CH}_3$



$\text{R} = \text{H}, \text{CH}_3$







$\text{X} = \text{NH}, \text{S}$



5.) *Arylaliphatic Mercaptans*: HSR^8 where R^8 is a 1—6 carbon branched or unbranched alkyl, cycloalkyl, alkenyl, or alkynyl group substituted by a phenyl or substituted phenyl group. Typical phenyl substituents include those mentioned under "Aryl Mercaptans".

5
10
15
20
25




EXAMPLES





30 6.) *Heteroarylaliphatic and Heterocyclicaliphatic Mercaptans*: HSR^8 wherein R^8 is a 1—6 carbon branched or unbranched alkyl, cycloalkyl, alkenyl, or alkynyl group substituted by a heteroaryl or heterocyclic group containing 1—4, O, N, or S atoms. The heteroaryl or heterocyclic group is unsubstituted or substituted by those substituents mentioned under "Aryl Mercaptans", (No. 3, above).

35
40
45
50
55
60
65

EXAMPLES




$n = 1, 2$




$\text{R}^1 = \text{OCH}_2\text{CH}_3$

EXAMPLES (continued)


5



10




15




X = O, S, NH

20




X = O, S, NH

25




X = O, S, NH

30




X = O, S, NH

35




X = O, S, NH

45




50



R¹ = H, CH₃

55




R¹ = H, CH₃

60

65


EXAMPLES (continued)

5




X = O, NH, NCH₃

10




R¹ = H, CH₃

15




R¹ = H, CH₃

20




R¹ = H, CH₃

25



R¹ = H, CH₃


30



R¹ = H, CH₃


35

40




R¹ = H, CH₃

45




n = 1-3, m = 1-3

50




R² = H, CH₃, R¹ = H, CH₃, NH₂

55



R¹ = H, CH₃

60




R¹ = H, CH₃

65


7.) Alkyl-Heteroatom-Alkyl Mercaptans, HSR^8
 wherein R^8 is



wherein $n = 2$ to 4 , $m = 2$ to 4 ; X is NR^9 , O or S ; and wherein R^9 is H , CH_3 , CH_2CH_3 , $\text{CH}_2\text{CH}_2\text{OH}$, or $\text{CH}_2\text{CH}_2\text{NH}_2$ and R^9 is OH , NH_2 , NHCH_3 , $\text{N}(\text{CH}_3)_2$,













Note, in the above representation, the methylene carbons may be branched; for example:




and the like.

The following HSR^8 are representative of this class:



As noted above, the compounds of the present invention may also generally be represented by the following structural formula: —



wherein X' is oxygen, sulfur or NR' (R' is hydrogen or loweralkyl having from 1 to 6 carbon atoms); and R³ is hydrogen, or, is representatively selected to provide the pharmaceutically acceptable salt, ester anhydride (R³ is acyl) and amide moieties known in the bicyclic β -lactam antibiotic art; R³ may also be a readily removable known blocking group.

Identification of the radical —COX'R³

In the generic representation of the compounds of the present invention (I, above), the radical represented by —COX'R³ is, *inter alia*, —COOH (X' is oxygen and R³ is hydrogen) and all radicals known to be effective as pharmaceutically acceptable ester, anhydride (R³ is acyl) and amide radicals in the bicyclic β -lactam antibiotic art, such as the cephalosporins and penicillins and nuclear analogues thereof.

Suitable blocking esters (R³, X' = O) include those selected from the following list which is representative:

(i) R³ = CR^aR^bR^c wherein at least one of R^a, R^b and R^c is an electron-donor, e.g., *p*-methoxyphenyl. The remaining R^a, R^b and R^c groups may be hydrogen or organic substituting groups. Suitable ester groups of this type include *p*-methoxybenzyloxycarbonyl.

(ii) R³ = CR^aR^bR^c wherein at least one of R^a, R^b and R^c is an electron-attracting group, e.g., *p*-nitrophenyl, trichloromethyl, and *o*-nitrophenyl. Suitable esters of this type include *p*-nitrobenzyloxycarbonyl, and 2,2,2-trichloroethoxycarbonyl.

(iii) R³ = CR^aR^bR^c wherein at least two of R^a, R^b and R^c are hydrocarbon such as alkyl, e.g., methyl or ethyl, or aryl, e.g., phenyl and the remaining R^a, R^b and R^c group, if there is one, is hydrogen. Suitable esters of this type include *t*-butoxycarbonyl, diphenylmethoxycarbonyl and triphenylmethoxycarbonyl.

Silyl esters, under this category of blocking groups, may conveniently be prepared from a halosilane of the formula:



wherein X' is a halogen such as chloro or bromo and R⁴ is alkyl, e.g., methyl, ethyl, *t*-butyl.

Pharmaceutically acceptable carboxyl derivatives of the present invention are those derived by reacting I with alcohols, acylating reagents for example. For example, esters and amides of interest are the above-listed starting materials and final products having the —COX'R³ group at the 3-position; wherein X' is oxygen, sulfur or NR' (R' is H or R³), and R³ is alkyl having 1—6 carbon atoms, straight or branched, such as methyl, ethyl or *t*-butyl; carbonylmethyl, including phenacyl; aminoalkyl including 2-methylaminoethyl, 2-diethylaminoethyl; alkanoyloxyalkyl wherein the alkanoyloxy portion is straight or branched and has 1—6 carbon atoms and the alkyl portion is straight or branched having 1—6 carbon atoms, such as pivaloyloxymethyl; haloalkyl wherein halo is chloro, and the alkyl portion is straight or branched having 1—6 carbon atoms, e.g., 2,2,2-trichloroethyl; alkenyl having 1—4 carbon atoms such, as 2-propenyl, 3-butenyl, and 4-butenyl; aralkyl and lower alkoxy- and nitro- substituted aralkyl such as benzyl, benzhydryl, *o*-nitrobenzyl, *p*-methoxybenzyl, and *p*-nitrobenzyl; phthalidyl; benzyloxyalkyl having 8—10 carbon atoms such as benzyloxymethyl, and (4-nitro) benzyloxymethyl.

In addition to the esters (and thio esters) listed above, amides are also embraced by the present invention, i.e., wherein X' is the



group. Representative of such amides are those wherein R' is selected from the group consisting of hydrogen and lower alkyl such as methyl and ethyl.

The most preferred —COX'R³ radicals of the present invention are those wherein (relative to Structure I above), X' is oxygen and R³ is hydrogen; loweralkyl having 1—4 carbon atoms; lower alkenyl such as 3-methylbutenyl, or 4-butenyl; benzyl and substituted benzyl such as p-nitrobenzyl; pivaloyloxymethyl, 3-phthalidyl; and phenacyl.

The compounds of the present invention (I) are valuable antibiotics active against various gram-positive and gram-negative bacteria and accordingly find utility in human and veterinary medicine. Representative pathogens which are sensitive to antibiotics I include: *Staphylococcus aureus*, *Escherichia coli*, *Klebsiella pneumoniae*, *Bacillus subtilis*, *Salmonella typhosa*, *Pseudomonas* and *Bacterium proteus*. The antibacterials of the invention are not limited to utility as medicaments; they may be used in all manner of industry, for example: additives to animal feed, preservation of food, disinfectants, and in other industrial systems where control of bacterial growth is desired. For example, they may be employed in aqueous compositions in concentrations ranging from 0.1 to 100 parts of antibiotic per million parts of solution in order to destroy and inhibit the growth of harmful bacteria on medical and dental equipment and as bactericides in industrial applications, for example in waterbased paints and in the white water of paper mills to inhibit the growth of harmful bacteria.

The products of this invention may be used in any of a variety of pharmaceutical preparations. They may be employed in capsule, powder form, in liquid solution, or in suspension. They may be administered by a variety of means; those of principal interest include: orally, topically or parenterally by injection (intravenously or intramuscularly).

Such tablets and capsules, designed for oral administration, may be in unit dosage form, and may contain conventional excipients, such as binding agents, for example, syrup, acacia, gelatin, sorbitol, tragacanth, or polyvinylpyrrolidone; fillers, for example, lactose, sugar, cornstarch, calcium phosphate, sorbitol, or glycerine; lubricants, for example, magnesium stearate, talc, polyethylene glycol, silica; disintegrants, for example, potato starch; or acceptable wetting agents such as sodium lauryl sulphate. The tablets may be coated according to methods well known in the art. Oral liquid preparations may be in the form of aqueous or oily suspensions, or solutions, or they may be presented as a dry product for reconstitution with water or other suitable vehicle before use. Such liquid preparations may contain conventional additives such as suspending agents, for example, sorbitol, methyl cellulose, glucose/sugar syrup, gelatin, hydroxyethylcellulose, or carboxymethyl cellulose. Suppositories will contain conventional suppository bases, such as cocoa butter or other glycerides.

Compositions for injection, the preferred route of delivery, may be prepared in unit dosage form in ampules, or in multidose containers. The compositions may take such forms as suspensions, solutions, or emulsions in oily or aqueous vehicles, and may contain formulatory agents such as suspending, stabilizing and/or dispersing agents. Alternatively, the active ingredient may be in powder form for reconstitution, at the time of delivery, with a suitable vehicle, such as sterile water.

The compositions may also be prepared in suitable forms for absorption through the mucous membranes of the nose and throat or bronchial tissues and may conveniently take the form of liquid sprays or inhalants, lozenges, or throat paints. For medication of the eyes or ears, the preparation may be presented in liquid or semi-solid form. Topical applications may be formulated in hydrophobic or hydrophilic bases as ointments, creams, lotions, paints, or powders.

The dosage to be administered depends to a large extent upon the condition and size of the subject being treated as well as the route and frequency of administration — the parenteral route by injection being preferred for generalized infections. Such matters, however, are left to the routine discretion of the therapist according to principles of treatment well known in the antibiotic art. In general, a daily dosage consists of from about 5 to about 600 mg of active ingredient per kg. of body weight of the subject in one or more treatments per day. A preferred daily dosage for adult humans lies in the range of from about 10 to 240 mg. of active ingredient per kg. of body weight. Another factor influencing the precise dosage regimen, apart from the nature of the infection and peculiar identity of the individual being treated, is the molecular weight of the chosen species of this invention (I).

The compositions for human delivery per unit dosage, whether liquid or solid, may contain from 0.1% to 99% of active material, the preferred range being from about 10—60%. The composition will generally contain from about 15 mg. to about 1500 mg. of the active ingredient; however, in general, it is preferable to employ a dosage amount in the range of from about 250 mg to 1000 mg. In parenteral administration, the unit dosage is usually the pure compound I in sterile water solution or in the form of a soluble powder intended for solution. For zwitterionic species described under Structure I, the pH of such solutions typically will correspond to the zwitterionic point; however, consideration of individual properties of solubility and stability may require such aqueous solutions to have a pH other than that of the zwitterionic point, for example in the range of 5.5 to 8.2.

In the foregoing word description of the above schematic reaction diagram for the total synthesis of the defined carbapenem antibiotics, it is to be understood that there is considerable latitude in selection of precise reaction parameters. Suggestion of this latitude and its breadth is generally indicated by the enumeration of equivalent solvent systems, temperature ranges, protecting groups, and range of identities of involved reagents. Further, it is to be understood that the presentation of the synthetic scheme as comprising distinct steps in a given sequence is more in the nature of a descriptive convenience than as a necessary requirement; for one will recognize that the mechanically dissected scheme represents a unified

scheme of synthesis and that certain steps, in actual practice, are capable of being merged, conducted simultaneously, or effected in a reverse sequence without materially altering the progress of synthesis.


The following examples recite a precise scheme of total synthesis. It is to be understood that the purpose of this recitation is to further illustrate the total synthesis and not to impose any limitation.

Temperature is in °C.

Example 1

Preparation of 4(S)-4-Iodomethylazetidin-2-one

STEP A



Benzyl (S)-azetidin-2-one-4-carboxylate

To a 1000 ml separatory funnel are added dibenzyl (S)-aspartate *p*-toluenesulfonic acid salt (48.6 g, 0.1 mole), ice-cold diethyl ether (300 ml), ice-cold water (100 ml), and ice-cold saturated aqueous potassium carbonate (50 ml). The mixture is shaken vigorously and the layers are separated. The aqueous portion is extracted with more cold diethyl ether (2 × 100 ml). The combined ether solution is washed with brine, dried with magnesium sulfate, and evaporated under vacuum to provide dibenzyl (S)-aspartate (31.4 g, 0.1 mole) as a colorless liquid.


The dibenzyl (S)-aspartate in anhydrous diethyl ether (200 ml) is cooled in an ice-bath under a nitrogen atmosphere. Trimethylchlorosilane (12.7 ml, 0.1 mole) is added to the stirred solution to give a white precipitate. Triethylamine (14.0 ml, 0.1 mole) is then added to the mixture. The cooling bath is removed and the mixture is stirred at room temperature (22–25°C) for 2 hrs. The mixture is then filtered directly into a 3-neck, 1.0 liter, round bottom flask fitted with a sintered glass funnel, magnetic stirrer, and a vacuum-nitrogen inlet. This operation is carried out under a blanket of nitrogen, care being taken to exclude atmospheric moisture. The sintered glass funnel is replaced by a stopper and the ether is evaporated under vacuum with stirring to provide dibenzyl (S)-N-trimethylsilylaspartate (35.5 g, 0.092 mole) as a slightly hazy oil.

Anhydrous diethyl ether (250 ml) is added to the flask containing the silyl derivative and the magnetic stirrer is replaced by a mechanical stirrer. The resulting solution is stirred under a nitrogen atmosphere with ice-bath cooling. Ethereal ethyl magnetic bromide (34 ml of a 2.94 M solution, 0.1 mole) is added dropwise over 40 min. to give a cream colored, stirable precipitate. The cooling bath is removed and the mixture is stirred at room temperature. After 1.5 hrs, a viscous gum forms. The mixture is allowed to stand overnight at room temperature. The mixture is then cooled in an ice-methanol bath while ammonium chloride saturated 2N hydrochloric acid (100 ml) is added slowly with stirring. The resulting mixture is diluted with ethyl acetate (100 ml) and water (100 ml) and the layers are separated. The aqueous portion is extracted with more ethyl acetate (3 × 100 ml). The combined organic solution is washed with water (200 ml), 5% aqueous sodium bicarbonate solution (100 ml), water (100 ml), and brine, dried with magnesium sulfate, and filtered. Evaporation of the solvent under vacuum gives an organic oil interspersed with a fine, granular precipitate (25.3 g). This material is dissolved in warm chloroform (75 ml), diluted with petroleum ether (125 ml), seeded, scratched, and cooled in an ice-bath. The precipitate is collected, washed with petroleum ether, and dried under vacuum to give benzyl (S)-azetidin-2-one-4-carboxylate (3.85 g) as an off-white solid mp 136–139°C. The mother liquors and washings are combined, diluted with petroleum ether to 500 ml, seeded, and left in a refrigerator for several days. The resulting precipitate is collected, washed with petroleum ether, and dried under vacuum to give additional product (0.82 g) as pale yellow crystals. Recrystallization of a sample from chloroform-petroleum ether gave the product as small, white flakes: mp 141–143°; $[\alpha]_D^{25} = -43.4^\circ$ (c 3.275 in CHCl_3); IR(CHCl_3) 3425, 1778, 1746 cm^{-1} ; ^1H NMR(CDCl_3) δ 3.00 (ddd, 1, $J=1.9, 3.2$, and 14.6Hz , H-3a), δ 3.35 (ddd, 1, $J=1.5, 5.4$, and 14.6Hz , H-3b), δ 4.20 (dd, 1, $J=3.2$ and 5.4Hz , H-4), δ 5.22 (s, 2, OCH_2Ph), δ 6.48 (m, 1, NH), 7.38 (s, 5, phenyl); mass spectrum m/e 205 (M^+), 163, 91, 70, 43.

Anal. Calcd. for $\text{C}_{11}\text{H}_{11}\text{NO}_3$: C, 64.38; H, 5.40; N, 6.83.

Found: C, 64.10; H, 5.70; N, 6.77.


STEP B



4(S)-4-Hydroxymethylazetidin-2-one

Sodium borohydride (3.69 g, 97.5 mmol) is added in one portion to a suspension of benzyl 4(S)-4-azetidin-2-one-4-carboxylate (20.0 g, 97.5 mmol) in 300 ml of absolute methanol at 0°C. The mixture is then allowed to warm slowly with periodic cooling being supplied to keep the internal temperature <30°C. After stirring for 2 hr., glacial acetic acid (23.4 g, 390 mmol) is added and the reaction mixture is concentrated under vacuum. The residue is treated with 500 ml of chloroform and filtered. The filtrate is concentrated under vacuum and the residue is chromatographed on 250 g of silica gel (4:1, chloroform:methanol) to yield 9.62 g (98%) of 4(S)-hydroxymethylazetidin-2-one as a white solid: m.p. 51–53°C; $[\alpha]_D^{25} = -68.0^\circ$ (C=2.676 in CHCl₃); IR (CHCl₃) 3410, 1765 cm⁻¹ 1H NMR (CDCl₃) δ 7.07 (1H, br. s, NH), δ 4.05 (1H, br. s, OH), δ 3.77 (2H, m, H4, H-5a or b), δ 3.58 (1H, dd, J=11, 6, H-5a or b), δ 2.97 (1H, ddd, J=14.5, 4.8, 1.3, H3b), δ 2.7 (1H, br. d, J=14.5, H3a); mass spectrum m/e 101 (M⁺), 83.


STEP C



4(S)-4-Methanesulfonyloxymethyl azetidin-2-one

Methane sulfonyl chloride (11.46 g, 100 mmol) is added dropwise by syringe to a solution of 4(S)-4-hydroxymethyl azetidin-2-one (10.1 g, 100 mmol) and triethyl amine (10.1 g 100 mmol) in 15 ml of dry methylene chloride at 0°C. (Warming is necessary in order to initially solubilize the alcohol. The resulting solution is then cooled to 0°C prior to addition of the other reagents). The resulting solution is stirred at 0°C for 1 hr. during which time a voluminous precipitate is produced. At the end of this time, the reaction mixture is filtered and the filtrate is concentrated under vacuum. The two solid residues are combined and treated with 500 ml of chloroform. The resulting mixture is filtered to yield substantially pure 4(S)-4-methanesulfonyloxymethyl azetidin-2-one as a white solid. The filtrate, which contains most of the triethylamine hydrochloride, is concentrated under vacuum and chromatographed on 200 g of silica gel (4:1 chloroform:methanol) to yield an additional quantity of mesylate. This material is combined with that obtained previously and recrystallized from chloroform to yield 15.57 (87%) of 4(S)-4-methanesulfonyloxymethylazetidin-2-one as colorless needles: m.p. 109.5–110.5°C; $[\alpha]_D^{25} = +25.8^\circ$ (C=1.025 in H₂O);


NMR (D₂O) δ 4.62 (1H, dd, J=11.2, 3.0, H-5a or b), δ 4.43 (1H, dd, J=11.2, 6, H-5a or b), δ 4.12 (1H, m, H4)



δ 3.19 (1H, dd, J=15, 4.5, H3b). δ 2.88 (1H, dd, J=15, 2.5, H3a); mass spectrum m/e 179 (M⁺), 136.

Anal: Calc: C, 33.51; H, 5.06; N, 7.82; S, 17.89
Found: C, 33.54; H, 5.08; N, 7.72; S, 17.93

STEP D




4(S)-4-Iodomethylazetidin-2-one

A mixture of 4(S)-4-methanesulfonyloxazetidin-2-one (11.8 g, 65.9 mmol) and powdered sodium iodide (19.8 g, 132 mmol) in 130 ml of acetone is heated at reflux for 6 hr. The resulting reaction mixture is concentrated *in vacuo*, treated with 200 ml of chloroform and filtered. The filtrate is washed with 2 x 50 ml of water and dried over magnesium sulfate. The organic phase is filtered, concentrated *in vacuo*, and chromatographed on 250 g of silica gel (ethyl acetate) to yield 11.94 g (86%) of 4(S)-4-iodomethylazetidin-2-one as a white solid. This material is recrystallized from ether-petroleum ether to yield white crystals: mp 91–92°C; $[\alpha]_D^{25} = -23.7^\circ$ (C=1.354 in CHCl_3); IR (CHCl_3) 3450, 1765 cm^{-1} ; ^1H NMR (CHCl_3) δ 6.13 (brs, N—Hk); δ 3.94 (m, 1H, Hc), δ 3.36 (m, 2H, Hd and e), δ 3.16 (ddd, 1H, J=14.9, 5.4, 2.3, Ha), δ 2.72 (d, d, d, 1H, J=14.9, 2.1, 2, Hb) mass spectrum m/e 211 (M^+), 168, 142, 127, 84.

Example 2


Preparation of (4S)-1-(t-Butyldimethylsilyl)-4-iodomethylazetidin-2-one



t-butyldimethylchlorosilane (7.51 g, 49.8 mmol) is added in one portion to an ice-cold, stirring solution of (4S)-4-iodomethylazetidin-2-one (10.0 g, 47.4 mmol) and triethylamine (5.04 g, 49.8 mmol) in anhydrous dimethylformamide (100 ml). A voluminous white precipitate forms almost immediately. The reaction mixture is stirred at 0–5° for 1 hour and then allowed to warm to room temperature. Most of the solvent is removed under vacuum to give a residue which is partitioned between diethyl ether (250 ml) and water. The ethereal phase is washed with 2.5N hydrochloric acid (50 ml), water (3 x 50 ml), and brine, dried with magnesium sulfate, filtered, and evaporated under vacuum to provide (4S)-1-(t-butyldimethylsilyl)-4-iodomethylazetidin-2-one (15.1 g) as a white solid. Recrystallization from petroleum ether — ethyl ether gives the product as colorless plates, mp 71–72°; n.m.r. (CDCl_3), δ 3.8 (m, 1), δ 2.6–3.6 (2 overlapping d of AB, 4) δ 1.0 (s, 9), δ 0.3 (s, 6), δ 0.25 (s, 6).

Example 3

Preparation of Benzyl (4S)-azetidin-2-one-4-carboxylate




A mixture of dibenzyl (S)-aspartate p-toluenesulfonic acid salt (48.6 g, 0.1 mole), diethylether (300 ml), water (100 ml), and saturated aqueous potassium carbonate (50 ml) is shaken vigorously. The layers are separated and the aqueous portion is extracted with more ether (2 x 100 ml). The combined ethereal extracts are washed with brine, dried with magnesium sulfate, filtered, and evaporated under vacuum to afford dibenzyl (S)-aspartate (31.5 g) as a water white liquid.

The dibenzyl (S)-aspartate in anhydrous diethyl ether (200 ml) is cooled in an ice bath and stirred under a nitrogen atmosphere while trimethylchlorosilane (12.7 ml, 0.1 mole) and triethylamine (14.0 ml, 0.1 mole) are added successively over a few minutes. The cooling bath is removed and the mixture is stirred at room temperature for 2 hours. The mixture is then filtered under a blanket of nitrogen into a three-neck, one-liter, round bottom flask fitted with a sintered glass funnel, vacuum-nitrogen inlet, and a mechanical stirrer. Additional anhydrous ether (2 x 50 ml) is used to wash the precipitate of triethylammonium hydrochloride. The funnel containing the precipitate is replaced by a dropping funnel and the ethereal filtrate of dibenzyl (4S)-N-trimethyl silyl-aspartate is cooled in an ice bath and stirred under a nitrogen atmosphere while 2.1M t-butyl magnesium chloride in ether (48 ml, 0.1 mole) is added drop wise over 9 minutes. A gummy precipitate forms during the addition. The cooling bath is then removed and the mixture is allowed to stand at room temperature overnight.

The mixture is cooled in an ice-bath and stirred vigorously while ammonium chloride saturated 2N hydrochloric acid (100 ml) is added over a few minutes. After stirring vigorously several more minutes, the mixture is diluted with water (100 ml) and ethyl acetate (100 ml) and the layers are separated. The aqueous portion is extracted with ethyl acetate (2 x 100 ml). The combined organic solution is washed with water (100 ml), 5% aqueous sodium bicarbonate (100 ml), and brine (100 ml), dried with magnesium sulfate, filtered, and evaporated under vacuum to a yellow semi-solid. Crystallization of this material from methylene chloride (100 ml)-petroleum ether (300 ml) provides the azetidinone product (8.2 g) as an off-white powder. The mother liquors are evaporated and the residue crystallized from diethyl ether to afford additional product (2.5 g) as a pale yellow product. The two crops are combined and recrystallized from methylene chloride to yield benzyl (4S)-azetidin-2-one-4-carboxylate (9.5 g) as nearly colorless crystals: mp 139–141°; $[\alpha]_D = -40.5^\circ$ (C2.0 in CHCl_3); IR (CHCl_3) 3425, 1778, 1746 cm^{-1} ; ^1H NMR (CDCl_3) δ 3.00 (ddd, H-3 β), 3.35 (ddd, H-3 α), 4.20 (dd, H-4), 5.22 (s, CH_2O), 6.48 (m, NH), 7.35 (s, phenyl); mass spectrum m/e 205 (M^+), 163, 91, 70, 43.

Example 4

(4S)-1-(t-butyldimethylsilyl)-4-[2,2-(trimethylenedithia)-2-trimethylsilylethyl]-azetidin-2-one




TMS = trimethylsilyl

A solution of 2-trimethylsilyl-1,3-dithiane (3.78 g, 19.69 mmole) in anhydrous tetrahydrofuran (25 ml) at 0°C is stirred under nitrogen while n-butyllithium in hexane (20.67 mmol) is added dropwise. The resulting solution is stirred for 15 min. at 0°C then cooled to -78°C (dry ice-acetone). A solution of (4S)-1-(t-butyldimethylsilyl)-4-iodomethylazetidin-2-one (6.40 g, 19.69 mmol) in 20 ml of anhydrous tetrahydrofuran is added slowly by syringe over ca. 5 min. The resulting solution is stirred at -78°C for 1 hr., then quenched by the addition of saturated aqueous ammonium chloride solution (10 ml) and allowed to warm to room temperature (22°C). The mixture is poured into a separatory funnel containing ethylether (200 ml) and water (100 ml). The organic phase is separated, washed with brine and dried over anhydrous magnesium sulfate. The solvent is removed *in vacuo* to yield a yellow oil. This material is filtered through a short silica gel column (25% ether in petroleum ether) to give 6.15 g (80%) of (4S)-1-(t-butyldimethylsilyl)-4-[2,2-(trimethylenedithia)-2-trimethylsilylethyl]-azetidin-2-one as a white solid, m.p. 71–73°C. n.m.r. (CDCl_3) δ 3.9 (1H, m, H-5), 2.2–3.6 (8H, overlapping m), δ 2.0 (2H, m, $\text{SCH}_2\text{CH}_2\text{CH}_2\text{S}$), δ 0.99 (9H, s, $\pm$ Si), δ 0.23 (15H, br. s, (CH_3)₂Si & (CH_3)₃Si). IR (CHCl_3) 2930, 2855, 1723 cm^{-1} .

Example 5

(3, *R,S,4R*)-1-(*t*-Butyldimethylsilyl)-3-[(*R,S*)-1-hydroxyethyl]-4-[2,2-(trimethylenedithia)-2-trimethylsilylethyl]-azetidin-2-one




A solution of diisopropylamine (10.5 mmol) in anhydrous tetrahydrofuran (40 ml) is cooled to -78°C (dry ice-acetone) and stirred under nitrogen atmosphere while *n*-butyllithium in hexane (10.5 mmol) is added slowly by syringe. After 15 min., a solution of (4*S*)-1-(*t*-butyldimethylsilyl)-4-[2,2-(trimethylenedithia)-2-trimethylsilylethyl]-azetidin-2-one (10.0 mmol) in anhydrous tetrahydrofuran (12 ml) is added slowly by syringe. The resulting solution is stirred at -78°C for 20 min. prior to the addition of acetaldehyde (30.0 mmol). After an additional 10 min. at -78°C the reaction is quenched by the addition of saturated aqueous ammonium chloride solution (10 ml) and allowed to warm to room temperature. The reaction mixture is diluted with ethyl acetate (150 ml) and washed with 2.5N hydrochloric acid solution (50 ml), water (50 ml) and brine (50 ml) and dried over magnesium sulfate. Removal of solvents *in vacuo* gives a white solid (4.6 g) which is chromatographed on 250 g of silica gel (1:1, ether:petroleum ether) to give four main product fractions with a total weight of 4.185 g (96.7%). Fraction No. 1- $R_f=0.62$, 85 mg. Fraction No. 2- $R_f=0.43$, 1.95 g (45%), (3*S,4R*)-1-(*t*-butyldimethylsilyl)-3-[(*S*)-1-hydroxyethyl]-4-[2,2-(trimethylenedithia)-2-trimethylsilylethyl]-azetidin-2-one. Fraction No. 3- $R_f=0.34$, 150 mg. mixture. Fraction No. 4- $R_f=0.28$, 2.0 g (46%), (3*S,4R*)-1-(*t*-butyldimethylsilyl)-3-[(*R*)-1-hydroxyethyl]-4-[2,2-(trimethylenedithia)-2-trimethylsilylethyl]-azetidin-2-one.

Example 6


(3*S,4R*)-1-(*t*-Butyldimethylsilyl)-3-(1-oxoethyl)-4-[2,2-(trimethylenedithia)-2-trimethylsilylethyl]-azetidin-2-one

STEP A



A solution of diisopropylamine (6.0 mmol) in anhydrous tetrahydrofuran (25 ml) is cooled to -78°C (dry ice-acetone) and stirred under a nitrogen atmosphere while *n*-butyllithium in hexane (6.0 mmol) is added by syringe. After 15 min., a solution of (4*S*)-1-(*t*-butyldimethylsilyl)-4-[2,2-(trimethylenedithia)-2-trimethylsilylethyl]-azetidin-2-one (3.0 mmol) in anhydrous tetrahydrofuran (3 ml) is added dropwise by syringe. The resulting solution is stirred at -78°C for 30 min., then added through a Teflon tube to a mixture of *N*-acetylpyrrolidine (6.0 mmol) and anhydrous tetrahydrofuran (25 ml) at -78°C . The resulting yellow reaction mixture is stirred at -78°C for 10 min., then quenched by addition of saturated aqueous ammonium chloride solution. The reaction mixture is poured into ether (200 ml) and extracted with 2.5N hydrochloric acid solution (50 ml), water (50 ml) and brine and dried over magnesium sulfate. Removal of solvents *in vacuo* gives a yellow oil which is chromatographed on silica gel (ether:petroleum ether) (1:2) to yield (3*S,4R*)-1-(*t*-butyldimethylsilyl)-3-(1-oxoethyl)-4-[2,2-(trimethylenedithia)-2-trimethylsilylethyl]-azetidin-2-one.

STEP B



15 Trifluoroacetic anhydride (6.0 mmol) is added by syringe to a solution of dimethylsulfoxide (8.0 mmol) in anhydrous methylene chloride (10 ml) at -78°C. The resulting mixture is stirred at -78°C for 20 min., during which time a white precipitate forms. A solution of (3*RS*,4*R*)-1-(*t*-butyldimethylsilyl)-3-(*RS*-1-hydroxyethyl)-4-[2,2-(trimethylenedithia)-2-trimethylsilyl]azetidin-2-one (4.0 mmol) in anhydrous methylene chloride (10 ml) is added by syringe and the resulting mixture is stirred at -78°C for 40 min.


20 Triethylamine (11.2 mmole) is added by syringe and the cooling bath is removed. After 1 hr. the reaction mixture is diluted with CH₂Cl₂ (100 ml) and washed with 2.5 N hydrochloric acid solution (50 ml), water (50 ml) and brine and dried over magnesium sulfate. Purification as above yields (3*S*,4*R*)-1-(*t*-butyldimethylsilyl)-3-(1-oxoethyl)-4-[2,2-(trimethylenedithia)-2-trimethylsilyl]azetidin-2-one. n.m.r. (CDCl₃) δ 4.23 (1H, br s, H-6), δ 4.2 (1H, m, H-5), δ 2.1-3.2 (6H, m), δ 2.27 (3H, s, CH₃-C=O), δ 2.0 (2H, m, SCH₂CH₂CH₂S), δ 0.96 (9H, s, ±Si), δ 0.25 (15H, br s (CH₃)₂Si and (CH₃)₃Si).

25

Example 7


(3*S*,4*R*)-1-(*t*-Butyldimethylsilyl)-3-[(*R*)-1-hydroxyethyl]-4-[2,2-(trimethylenedithia)-2-trimethylsilyl]azetidin-2-one

30



45 K-Selectride (potassium tri-*sec*-butylborohydride) (4.8 mmol) in a solution of tetrahydrofuran is added dropwise by syringe to a mixture of (3*S*,4*R*)-1-(*t*-butyldimethylsilyl)-3-(1-oxoethyl)-4-[2,2-(trimethylenedithia)-2-trimethylsilyl]azetidin-2-one (2.0 mmol) and potassium iodide (2.0 mmol) in anhydrous ether (20 ml) at room temperature. The resulting mixture is stirred at room temperature for 2.5 hr., then quenched by addition of glacial acetic acid (9.6 mmol). The resulting mixture is diluted with ethyl acetate (50 ml) and filtered through celite. The solvents are removed *in vacuo* to give an oil which is chromatographed on silica gel (1:1, ether: petroleum ether) to give (3*S*,4*R*)-1-(*t*-butyldimethylsilyl)-3-[(*R*)-1-hydroxyethyl]-4-[2,2-(trimethylenedithia)-2-trimethylsilyl]azetidin-2-one as a white solid, n.m.r. (CDCl₃ + D₂O) δ 4.23 (1H, dq, J=7.5, 7, H-8) δ 3.78 (1H, ddd, J=7.5, 3, 2.2, H-5) δ 3.18 (1H, dd, 7.5, 2.2, H-6), δ 2.5-3.0 (4H, m, -SCH₂CH₂CH₂S- δ 2.35


50



δ 2.0 (2H, m, SCH₂CH₂CH₂S) δ 1.33 (3H, d, J=7, CH₃-), δ 0.98 (9H, s, ±Si) δ 0.26 (15H, br s, (CH₃)₂Si + (CH₃)₃Si).

65

Example 8

(3*S*,4*R*)-1-(*t*-Butyldimethylsilyl)-3-[(*R*)-1-hydroxyethyl]-4-(2-oxo-2-trimethylsilylethyl)-azetidin-2-one

A mixture of mercuric oxide (6.93 mmol), mercuric chloride (10.2 mmol) and (3*S*,4*R*)-1-(*t*-butyldimethylsilyl)-3-[(*R*)-1-hydroxyethyl]-4-[2,2-(trimethylenedithia)-2-trimethylsilylethyl]-azetidin-2-one (4.62 mmol) in 5% aqueous methanol (25 ml) is heated at reflux for 45 min. During this time, the color of reaction mixture changes from orange to off-white. The mixture is cooled and filtered and the filter cake is washed several times with methanol. The combined filtrate and washings are concentrated to ~5 ml *in vacuo*, then diluted with ethyl acetate (100 ml) and washed with saturated aqueous ammonium chloride solution (2 × 50 ml) and brine. The organic phase is dried over magnesium sulfate and concentrated *in vacuo* to yield a pale yellow oil. This material is chromatographed on silica gel (ether) to yield (3*S*,4*R*)-1-(*t*-butyldimethylsilyl)-3-[(*R*)-1-hydroxyethyl]-4-(2-oxo-2-trimethylsilylethyl)-azetidin-2-one, 1.38 g (87%), as a white solid, m.p. 82–84°C. n.m.r. (CDCl₃-D₂O) δ 3.6–4.3 (2H, m, H-5, H-8) δ 3.12

25


(2H, center of d of AB, J=18, 4, 8.5, —CH₂—C(=O)—)

30 δ 2.7 (1H, dd, J=7.5, 2, H-6), δ 1.27 (3H, d, J=6.5, CH₃—) δ 0.99 (9H, s, ±Si), δ 0.3 (15H, br.s, (CH₃)₃Si & (CH₃)₂Si). I.R. (CHCl₃) 3450, 2930, 2855, 1737, 1635 cm⁻¹.

Example 9

(3*S*,4*R*)-1-(*t*-Butyldimethylsilyl)-3-[(*R*)-1-hydroxyethyl]-4-carboxymethyl-azetidin-2-one

35




m-Chloroperbenzoic acid (1.00 mmol) is added to a solution of (3*S*,4*R*)-1-(*t*-butyldimethylsilyl)-3-[(*R*)-1-hydroxyethyl]-4-(2-oxo-2-trimethylsilylethyl)-azetidin-2-one (1.00 mmol) in chloroform (4 ml). The resulting solution is heated at reflux for 4 hr, then cooled, concentrated *in vacuo*, and the residue chromatographed on silica gel (2% glacial acetic acid in methylene chloride). (3*S*,4*R*)-1-(*t*-butyldimethylsilyl)-3-[(*R*)-1-hydroxyethyl]-4-carboxymethyl-azetidin-2-one, 238 mg (83%) is isolated as a colorless solid, R_f = 0.25. n.m.r. (CDCl₃ and D₂O) δ 3.6–4.3 (2H, m, H-5, H-8), δ 2.98 (1H, dd, J=7, 2.1 H-6), δ 2.7 (2H, d, of ABq) —CH₂CO₂H), δ 1.29 (3H, d, J=6, CH₃—) δ 0.95 (9H, s, Si±), δ 0.25 (6H, s, (CH₃)₂—Si).

50


Example 10

(3*S*,4*R*)-1-(*t*-Butyldimethylsilyl)-3-[(*R*)-1-hydroxyethyl]-4-(3-*p*-nitrobenzyloxycarbonyl-2-oxopropyl)-azetidin-2-one


55



1,1'-Carbonyldimidazole (1.10 mmol) is added in one portion to a solution of (3*S*,4*R*)-1-(*t*-butyldimethylsilyl)-3-[(*R*)-1-hydroxyethyl]-4-carboxymethyl-azetidin-2-one (1.0 mmol) in anhydrous tetrahydrofuran (5 ml) at room temperature. The resulting solution is stirred at room temperature for 6 hours. In a second flask, magnesium ethoxide (5 mmol) is added in one portion to a solution of the mono-*p*-nitrobenzyl ester of malonic acid (10 mmol) in anhydrous tetrahydrofuran (25 ml). The resulting mixture is stirred at room temperature for 1 hr, then the tetrahydrofuran is removed at the pump and the gummy residue is triturated with ether to yield the magnesium salt as an off-white solid. (1.1 mmol) of this magnesium salt is then added to the first reaction flask and the resulting mixture is stirred at room temperature for 18 hrs. The reaction mixture is then poured into 50 ml of ether, washed with 0.5 N hydrochloric acid solution (20 ml), water (20 ml), saturated aqueous sodium bicarbonate solution (20 ml), brine and dried over magnesium sulfate. Removal of solvents *in vacuo* gives an oil which is chromatographed on silica gel (ether) to yield (3*S*,4*R*)-1-(*t*-butyldimethylsilyl)-3-[(*R*)-1-hydroxyethyl]-4-(3-*p*-nitrobenzyloxycarbonyl-2-oxopropyl)-azetidin-2-one. n.m.r. ($\text{CDCl}_3 - \text{H}_2\text{O}$) δ 8.24, 8.10, 7.52, 7.38 (2H, AB, aromatic), δ 5.26 (2H, S, $-\text{CH}_2-\text{Ar}$), δ 3.5–4.2 (2H, m, H-5, H-8), δ 2.6–3.3




δ 1.3 (3H, d, $J=6.6$, CH_3-) δ 0.98 (9H, S, $\pm\text{Si}-$) δ 0.25 (6H, S,



Example 11


(3*S*,4*R*)-3-[(*R*)-1-hydroxyethyl]-4-(3-*p*-nitrobenzyloxycarbonyl-2-oxopropyl)-azetidin-2-one



A solution of (3*S*,4*R*)-1-(*t*-butyldimethylsilyl)-3-[(*R*)-1-hydroxyethyl]-4-(3-*p*-nitrobenzyloxycarbonyl-2-oxopropyl)-azetidin-2-one (1.0 mmol) in 20 ml of 9:1 (v/v) methanol-water is cooled to 0°C. Concentrated hydrochloric acid (0.34 ml) is added and the resulting solution is stirred at 0°C for 15 min., then allowed to warm to room temperature. After 2.5 hrs, at room temperature the reaction mixture is diluted with ethyl acetate (25 ml), washed with water (10 ml) and brine, dried over magnesium sulfate and concentrated *in vacuo* to yield (3*S*,4*R*)-3-[(*R*)-1-hydroxyethyl]-4-(3-*p*-nitrobenzyloxycarbonyl-2-oxopropyl)-azetidin-2-one.

Example 12


Preparation of (3*S*,4*R*)-3-[(*R*)-1-hydroxyethyl]-4-[3-(4-nitrobenzyl)oxycarbonyl-2-oxo-3-diazopropyl]-azetidin-2-one



Triethylamine (263 mg, 2.6 mmol) is added by syringe to a mixture of (3*S*,4*R*)-3-[(*R*)-1-hydroxyethyl]-4-[3-(4-nitrobenzyl)oxycarbonyl-2-oxopropyl]azetidin-2-one (253 mg, 0.72 mmol) and *p*-carboxybenzene sulfonyl azide (196 mg, 0.84 mmol) in dry acetonitrile (6 ml) at 0°C. When addition is complete the cooling bath is removed and the reaction mixture is stirred at room temperature for 1 hour. The mixture is then diluted with ethyl acetate (50 ml) and filtered. The filtrate is concentrated *in vacuo* and the residue is chromatographed on a short silica gel column (ethyl acetate) to yield 222 mg., (81% overall from (3*S*,4*R*)-1-(*t*-butyldimethylsilyl)-3-[(*R*)-1-(*t*-butyl dimethylsilyloxy)ethyl]-4-[3-(4-nitrobenzyl)oxycarbonyl-2-oxo-3-diazopropyl]azetidin-2-one) of (3*S*,4*R*)-3-(*R*)-1-hydroxyethyl-4-[3-(4-nitrobenzyl)oxycarbonyl-2-oxo-3-diazopropyl]azetidin-2-one as a white solid m.p. (dec.) 163°C. IR (CHCl₃, CM⁻¹) 3410, 2132, 1756, 1718, 1650, 1350, 1280, 1120; n.m.r. (CDCl₃) δ 7.9 (2d-aromatic, 4), δ 5.4 (s, 2), δ 6.2 (brs, 1), δ 4.1 (m, 2), δ 2.6—3.6 (m, 4), δ 1.32 (d, 3, J=6.2).


Example 13

Preparation of (5*R*,6*S*) *p*-Nitrobenzyl 6-[(*R*)-1-hydroxyethyl]-1-azabicyclo[3.2.0]heptan-3,7-dione-2-carboxylate



A suspension of (3*S*,4*R*)-3-[(*R*)-1-hydroxyethyl]-4-[3-(4-nitrobenzyl)oxycarbonyl-2-oxo-3-diazopropyl]azetidin-2-one (56.4 mg, 0.15 mmol) and rhodium (II) acetate (0.1 mg) in dry benzene (3 ml) is deoxygenated by bubbling through nitrogen for 10 minutes. The mixture is then heated to 78°C for 1 hour. During heating the solid starting material gradually goes into solution. The mixture is then cooled, filtered to remove the catalyst, and the filtrate is concentrated *in vacuo* to yield (5*R*,6*S*) *p*-nitrobenzyl 6-[(*R*)-1-hydroxyethyl]-1-azabicyclo[3.2.0]heptan-3,7-dione-2-carboxylate 51 mg (98%) as a colorless oil which slowly crystallized at room temperature (22°C).

Physical Properties:



PNB = *p*-nitrobenzyl


n.m.r.: (300 MHz, CDCl₃) δ 8.26, 7.54 (aromatic, 4), 5.29 (AB, 2), 4.77 (s, 1), 4.32 (dg, 1, J=6.6, 7), 4.16 (ddd, 1, J=7, 7.5, 2.2), 3.21 (dd, 1, J=7, 2.2), 2.94 (dd, 1, J=19.5, 7), 2.50 (dd, 1, J=19.5, 7.5), 2.2 (brs, 1), 1.37 (d, 3, J=6.6).

I.R.: (CHCl₃, CM⁻¹) 1770, 1758, 1610, 1522, 1353

m.p. 110—111°C.

Example 14


Preparation of *p*-Nitrobenzyl oxycarbonylaminoethanethiol



To 600 ml diethyl ether (Et₂O) — 75 ml H₂O in an ice bath with stirring is added 3.2 g cysteamine hydrochloride (mw = 114; 28.1 mmole). A solution of 7.14 g NaHCO₃ (mw = 84; 85 mmole) in 75 ml H₂O is added. The ice bath is removed, and at room temperature a solution of 6.75 g *p*-nitrobenzylchloroformate (mw = 216; 31.3 mmole) in 270 ml Et₂O is added dropwise over a period of one hour. After 10 additional minutes, the layers are separated. The ether layer is extracted with 150 ml 0.25 N HCl, and then with 200 ml brine. Each aqueous layer is then backwashed successively with 100 ml Et₂O. The combined Et₂O layers are dried over anhydrous MgSO₄, filtered, and concentrated under a N₂ stream. The crystalline residue is slurried in a small amount of ether, filtered, and the pale yellow crystals are dried under high vacuum to give 4.7 g. *p*-nitrobenzyloxycarbonylaminoethanethiol (65% yield). NMR (CDCl₃): 8.18 (d, J=8Hz, aromatic protons ortho to nitro), 7.47 (d, J=8Hz, aromatic protons meta to nitro), 5.27 (—NH—), 5.20 (s, —CH₂—NH—), 2.67 (m, —CH₂—SH), 1.35 (t, J=8.5Hz, —SH) in ppm downfield from TMS. IR (CHCl₃ solution): carbonyl- 1725 cm⁻¹. M.S.: Molecular ion-256, (M-47) at 209, (M-136) at 120, +CH₂O⁺pNO₂ at 136.

Example 15


15 Preparation of (5*R*,6*S*) *p*-Nitrobenzyl 3-[2-(*p*-nitrobenzyloxycarbonylaminoethylthio)-6-[(*R*)-1-hydroxyethyl]-1-azabicyclo[3.2.0]hept-2-en-7-one-2-carboxylate



(5*R*,5*S*) *p*-Nitrobenzyl 6-[(*R*)-1-hydroxyethyl]-1-azabicyclo[3.2.0]heptan-3,7-dione-2-carboxylate (51 mg, 0.147 mmol) is dissolved in acetonitrile (3 ml) and the resulting solution is cooled to 0°C. Diisopropylethylamine (22 mg, 0.17 mmol) is added by syringe and the resulting solution is stirred at 0°C for 1 minute prior to the addition of a solution of freshly recrystallized *p*-toluene sulfonic anhydride (51 mg, 0.156 mmol) in dry acetonitrile (1 ml). The resulting solution is stirred at 0°C for 1 hour to provide (5*R*,6*S*) *p*-nitrobenzyl 3-(*p*-toluenesulfonyloxy)-6-[(*R*)-1-hydroxyethyl]-1-azabicyclo[3.2.0]hept-2-en-7-one-2-carboxylate, then cooled to -25°C. Diisopropylethylamine (80.5 mg, 0.624 mmol) is added by syringe followed shortly thereafter by a solution of *N*-*p*-nitrobenzyloxycarbonylcysteamine (40 mg, 0.156 mmol) in 1 ml of dry acetonitrile. The reaction mixture is then stored in a refrigerator for 70 hr. The mixture is diluted with 25 ml of ethyl acetate washed with brine and dried over magnesium sulfate. Solvents are removed *in vacuo* to yield a yellow oil which is chromatographed on a silica gel plate (ethyl acetate, R_f = 0.4) to yield (5*R*,6*S*) *p*-nitrobenzyl-3-[2-(*p*-nitrobenzyloxycarbonylaminoethylthio)-6-[(*R*)-1-hydroxyethyl]-1-azabicyclo[3.2.0]hept-2-en-7-dione-2-carboxylate as a yellow solid, m.p. 167—169°C. IR(Nujol mull) 1773 and 1690 cm⁻¹; n.m.r. (CDCl₃) δ 7.54—8.26 (overlapping ABq, 4), δ 5.40 (ABq, 2), δ 5.22 (s, 2), δ 4.27 (m, 2), δ 3.47 (m), δ 3.23 (dd, 1), δ 3.14 (dd, 1), δ 3.40 (dd, 1), δ 3.04 (m, 2), δ 1.37 (d, 3).

Example 16

Preparation of Thienamycin




60 A mixture of *N*-*p*-nitrobenzyloxycarbonyl thienamycin *p*-nitrobenzyl ester (10 mg, 0.017 mmol) and 10% Pd/C-Bolhofer type in tetrahydrofuran (2 ml), 0.1 M dipotassium hydrogen phosphate solution (1.4 ml) and 2-propanol (0.2 ml) is hydrogenated at 2.76 bar (40 psi) on the Parr shaker for 30 minutes. The mixture is then filtered and the catalyst is washed with water (3 × 3 ml). The combined filtrate and washings are extracted with ethyl acetate-ethyl ether then concentrated to ~3 ml and lyophilized. The resulting white powder is identical to natural thienamycin in all respects.

0037082


Example 17

Preparation of



5R, 6S, 8S

Step A:
(3S,4R)-1-(t-Butyldimethylsilyl)-3-[(1-oxo-2,2,2-trifluoroethyl)-4-[2,2-(trimethylenedithia)-2-trimethylsilylethyl]-azetidin-2-one



A solution of diisopropylamine (41.1 mmol) in freshly distilled tetrahydrofuran (200 ml) is cooled to -78°C and stirred under a nitrogen atmosphere while n-butyllithium in hexane (41.1 mmol) is added by syringe. After 15 minutes, a solution of (4S)-1-(t-butyl dimethylsilyl)-4-[2,2-(trimethylenedithia)-2-trimethylsilylethyl]azetidin-2-one (18.69 mmol) in dry tetrahydrofuran (20 ml) is added slowly by syringe. The resulting solution is stirred at -78°C for 3 minutes, then added through a Teflon tube to a solution of S-ethyltrifluoromethylthioacetate (41.1 mmol) in tetrahydrofuran (120 ml). The total time required for the addition is 8 minutes. The resulting solution is stirred at -78°C for an additional 10 minutes, then quenched by the addition of saturated aqueous ammonium chloride solution (50 ml). The reaction mixture is then diluted with ether (500 ml) and washed with 50 ml of 2.5 N hydrochloric acid solution. The phases are separated and the aqueous phase is backwashed with ether (100 ml). The organics are combined, washed with water (100 ml) and brine (100 ml) and dried over anhydrous magnesium sulfate. The resulting solution is decolorized by brief heating with activated charcoal and the solvents are removed *in vacuo* to give an off-white solid (9.6 mg). This material is recrystallized from petroleum ether to give 7.03 g (78%) of white crystals, m.p. $120.5-122.5^{\circ}\text{C}$.

I.R. (CHCl_3 , cm^{-1}) 1767, 1736, 1318.

N.M.R. (CDCl_3) δ 4.6 (1H, d, $J=2.6\text{ Hz}$, H_3), 4.2 (1H, ddd, $J=2.6, 6.5, 8.8\text{ Hz}$, H_4), 2.3-3.2 (6H, m), 2.0 (2H, m, $-\text{SCH}_2\text{CH}_3\text{CH}_2\text{S}-$), 0.9 (9H, s, $\text{tBuMe}_2\text{Si}-$), 0.2 (6H, 2S, tBuMe_2Si) 0.16 (9H, s, Me_3Si)

Mass spectrum (m/e) 485, 412, 388.


Step B:
(3S,4R)-1-(t-Butyldimethylsilyl)-3-[(S)-1-hydroxy-2,2,2-trifluoroethyl]-4-[2,2-(trimethylenedithia)-2-trimethylsilylethyl]azetidin-2-one



A partial suspension of sodium borohydride (10.0 mmol) in isopropanol (10 ml) is added rapidly to a solution of (3*S*,4*R*)-1-(*t*-butyldimethylsilyl)-3-(1-oxo-2,2,2-trifluoroethyl)-4-[2,2-(trimethylenedithia)-2-trimethylsilylethyl]-azetidin-2-one (10.0 mmol) in anhydrous tetrahydrofuran (50 ml) at -78°C . The resulting mixture is stirred at -78°C for 30 min, then allowed to warm to room temperature. Excess sodium borohydride is decomposed by recooling the reaction mixture to 0°C and carefully adding 2.5 N hydrochloric acid solution (20 ml). The reaction mixture is then poured into ether (250 ml), washed with water (50 ml) and brine (50 ml) and dried over anhydrous magnesium sulfate. Removal of solvents *in vacuo* gives a colorless oil which is chromatographed on silica gel (150 g), (2:1 petroleum ether:ether) to provide 3.24 g (66.8%) of (3*S*,4*R*)-1-(*t*-butyldimethylsilyl)-3-[(*S*)-1-hydroxy-2,2,2-trifluoroethyl]-4-[2,2-(trimethylenedithia)-2-trimethylsilylethyl]-azetidin-2-one. IR (CHCl_3 , cm^{-1}) 3320, 1745, 1332. NMR (CDCl_3) δ 4.45 (1H, brs, OH), 3.9–4.9 (2H, overlapping m, $\text{H}_5 + \text{H}_8$), 3.4 (1H, dd, $J=9, 2.3$, H_6), 2.8 (4H, m, 2.4 (2H, m), 2.0 (2H, m), 1.0 (9H, s, $\text{t-BuMe}_2\text{Si}$), 0.3 (15H). This reaction also provides 1.04 g (21.3%) of the 8-*R* epimer of the above compound.

Step C:


(3*S*,4*R*)-1-(*t*-Butyldimethylsilyl)-3-[(*S*)-1-hydroxy-2,2,2-trifluoroethyl]-4-(2-oxo-2-trimethylsilylethyl)-azetidin-2-one



Mercuric oxide (10.8 mmol) and mercuric chloride (15.8 mmol) are added successively to a solution of (3*S*,4*R*)-1-(*t*-butyldimethylsilyl)-3-[(*S*)-1-hydroxy-2,2,2-trifluoroethyl]-4-[2,2-(trimethylenedithia)-2-trimethylsilylethyl]-azetidin-2-one (7.19 mmol) in 5% aqueous methanol (70 ml). The resulting mixture is heated at reflux for 1 hr, then cooled to room temperature and filtered. The filter cake is washed with additional methanol (2×30 ml) and the combined filtrate and washings are concentrated *in vacuo*. The residue is dissolved in ether (150 ml) and washed with saturated aqueous ammonium chloride solution (2×50 ml). The aqueous phase is backwashed with ether (100 ml) and the combined organics are washed with brine (50 ml) and dried over anhydrous magnesium sulfate. Removal of solvents *in vacuo* gives 2.94 g of an off-white solid. This material is chromatographed on silica gel (120 g, eluted with 3:2 petroleum ether:ether) to give 2.47 g (87%) of a white solid, m.p. $83-85^{\circ}\text{C}$. IR (CHCl_3 , cm^{-1}) 3360, 1740, 1635, 1333. NMR ($\text{CDCl}_3 + \text{D}_2\text{O}$) δ 3.9–4.5 (2H, overlapping m, H_5 and H_8), 3.0 (2H, 2dd, $J=18, 4.4$, $J=18, 7.2$ $\text{H}_1 \text{ a} + \text{b}$), 3.2 (1H, dd, $J=2.7, 5.5$, H_6), 1.0 (9H, s, $\text{t-BuMe}_2\text{Si}$), 0.2 (15H, $\text{t-BuMe}_2\text{Si}$ - and Me_3Si).

Step D:

(3*S*,4*R*)-1-(*t*-Butyldimethylsilyl)-3-[(*S*)-1-hydroxy-2,2,2-trifluoroethyl]-4-carboxymethyl-azetidin-2-one



A solution of (3*S*,4*R*)-1-(*t*-butyldimethylsilyl)-3-[(*S*)-1-hydroxy-2,2,2-trifluoroethyl]-4-(2-oxo-2-trimethylsilylethyl)-azetidin-2-one (2.52 mmol) and 30% hydrogen peroxide (12.6 mmol) in methanol (2.5 ml) is heated at $45-50^{\circ}\text{C}$ for 3 hr. The reaction mixture is then cooled to 0°C and dimethylsulfide (1 ml) is added. The ice bath is removed and the reaction mixture is monitored with starch iodide paper. When no oxidizing agent remains, the reaction mixture is concentrated *in vacuo* and the residue is dissolved in 2:1 petroleum ether:ether (100 ml) and washed with water (3×15 ml), then dried over anhydrous magnesium sulfate. Removal of solvents *in vacuo* gives 861 mg of a white solid which is recrystallized from petroleum ether-ether to yield 745 mg (87%) of white crystals, m.p. $134-136^{\circ}\text{C}$.


0037082

IR (CHCl₃, cm⁻¹) 3350 (very broad), 1738 (br), 1335.

NMR (acetone-d₆) δ 4.2—4.7 (2H, overlapping multiplets, H5 and H8), 3.65 (1H, dd, H6), 2.8 (2H, br.d, H1 A + B), 1.0 (9H, s, t-BuMe₂Si-) 0.3 (6H, 2d, tBuMe₂Si-).

5 Step E:


Following the procedure of Examples 10—16 except substituting an equivalent amount of the azetidinone of Example 17, Step D, for the azetidinone of Example 10, there is obtained:



5R, 6S, 8S

Example 18

Following the procedures of the foregoing Examples and text, the azetidinones of Table I are obtained; appropriate annotation is provided under the "Remarks" column.



TMS = trimethylsilyl

TABLE I

Compound	R ⁶	R ⁷	Remarks
1.)	(CH ₃) ₂ CH	H	As in Example 5, but substitute equivalent amount of isopropyl iodide for acetaldehyde.
2.)	CH ₃	H	As in Example 5, but using an equivalent amount of methyl iodide for acetaldehyde.
3.)	HOCH ₂	CH ₃	As in Example 5, but use compound 2., and excess formaldehyde introduced as a gas just above surface of stirred solution.
4.)	$\begin{array}{c} \text{OH} \\ \\ \phi\text{CH}_2\text{CH} \end{array}$	H	As in Example 5, but using an equivalent amount of phenyl acetaldehyde for acetaldehyde.
5.)	$\begin{array}{c} \text{OH} \\ \\ \text{CH}_3\text{CH} \end{array}$	CH ₃	Using the procedure of Example 5 upon compound 2 of Table I.
6.)	ϕCH_2	H	As in Example 5, but substitute benzyl-bromide for acetaldehyde.
7.)	$\begin{array}{c} \text{OH} \\ \\ \text{CH}_3\text{CH} \end{array}$	ϕCH_2	As in Example 5, but using compound 6 as substrate.
8.)	$\begin{array}{c} \text{OMs} \\ \\ \text{CH}_3\text{CH} \end{array}$ Ms = mesyl	H	Obtained from the product of Example 5 and methanesulfonyl chloride and triethylamine in methylene chloride at 0°.
9.)	$\begin{array}{c} \text{N}_3 \\ \\ \text{CH}_3\text{CH} \end{array}$	H	Obtained from compound 8 on treatment with LiN ₃ in DMF at 60°.
10.)	$\begin{array}{c} \text{NH}_2 \\ \\ \text{CH}_3\text{CH} \end{array}$	H	Obtained from compound 9 by reduction with H ₂ S and Et ₃ N in CH ₂ Cl ₂ .
10a.)	$\begin{array}{c} \text{NHCO}_2\text{PNB} \\ \\ \text{CH}_3\text{CH} \end{array}$	H	Obtained from compound 9 on treatment with ClCO ₂ PNB and DMPA in CH ₂ Cl ₂ at 0°.
11.)	$\begin{array}{c} \text{OH} \\ \\ (\text{CH}_3)_2\text{CHCH} \end{array}$	H	As in Example 5, but substituting isobutyraldehyde for acetaldehyde.

ϕ = phenyl.

0037082

TABLE I (Continued)










Compound	R ⁶	R ⁷	Remarks
25.)		H	As in Example 5, but use cyclopentanone instead of acetaldehyde.
25a.)		H	As in Example 17, Steps A & B, (or, equivalently, the procedure of Exs. 6 & 7) but use an equivalent amount of chloroacetylimidazole instead of S-ethyltrifluoromethylthioacetate.
25b.)		CH ₃	As in Example 18, Table I, No. 25a, but starting with azetidinone of Example 18, Table I, No. 3.
26.)		H	As in Example 17, Step A, but use ethyl monofluorothioacetate instead of S-ethyltrifluoromethylthioacetate.
27.)		H	As in Example 17, Step B, but substitute product No. 26, Table I, Example 14, and use sodium borohydride as reductant.
28.)		H	As in Example 5, but use azidoacetaldehyde instead of acetaldehyde.
29.)		H	As in Example 5, but substituted p-nitrobenzyl bromoacetate for acetaldehyde.
30.)		H	As in Example 17, Step A, but substituted N-methoxyacetylimidazole.
31.)		H	Obtained by employing the procedure of Example 17, Step B, on compound No. 30, Table I, Example 14.
32.)		H	As in Example 17, Step A, but substitute ethyl difluorothioacetate.

TABLE I (Continued)

5	Compound	R ⁶	R ⁷	Remarks
10	33.)	$\begin{array}{c} \text{OH} \\ \\ \text{CF}_2\text{CHCH} \end{array}$	H	Obtained from No. 32, above, using the procedure of Example 17, Step B, but substituting sodium borohydride as the reducing agent.
15	34.)	$\begin{array}{c} \text{PNBOCOCH}_2 \\ \\ \text{O} \end{array}$	CH ₃	Obtained from No. 3, Table I, Example 18 with p-nitrobenzyl chloroformate and 4-dimethylaminopyridine in methylene chloride.
20				
25	35.)	$\begin{array}{c} \text{O} \\ \\ \text{PNBOCOCH}_2\text{CH}_2 \end{array}$	H	Obtained from No. 16, Table I, Example 18, by reaction with p-nitrobenzyl chloroformate and triethylamine in methylene chloride.
30				
35	36.)	$\begin{array}{c} \text{O} \\ \\ \text{PNBOCOCH}_2\text{CH}_2 \end{array}$	CH ₃	Obtained from No. 24, Table I, Example 18 as described for the preceding compound No. 35.
40	37.)	HOCH ₂	H	As in Example 5, but use excess formaldehyde instead of acetaldehyde.
45	38.)	$\begin{array}{c} \text{PNBOCOCH}_2 \\ \\ \text{O} \end{array}$	H	Obtained from compound 36, above, and p-nitrobenzylchloroformate in methylene chloride containing 4-dimethylaminopyridine.

Example 19

Following the foregoing Examples and text, particularly Example 13, the representative intermediates of the present invention are obtained when the indicated substitution from Example 18 is made into the scheme of Example 13.



R = PNB (p-nitrobenzyl)

0037082

TABLE II

Compound	R ⁶	R ⁷	Remarks
1.)	(CH ₃) ₂ CH	H	
2.)	CH ₃	H	
3.)	$\text{PNBOC}\overset{\text{O}}{\parallel}\text{COCH}_2$	CH ₃	The primary alcohol, No. 3, Table I, Example 18 is protected as shown by reacting with an equivalent amount of ClCO ₂ PNB in the presence of DMAP (di-methylaminopropane) in methylene chloride.
4.)	$\text{ØCH}_2\overset{\text{OH}}{\text{CH}}$	H	
5.)	$\text{CH}_3\overset{\text{OH}}{\text{CH}}$	CH ₃	
6.)	ØCH ₂	H	
7.)	$\text{CH}_3\overset{\text{OH}}{\text{CH}}$	ØCH ₂	
8.)	$\text{CH}_3\overset{\text{N}_3}{\text{CH}}$	H	
9.)	$\text{CH}_3\overset{\text{NHCO}_2\text{PNB}}{\text{CH}}$	H	
10.)	$(\text{CH}_3)_2\text{CH}\overset{\text{OH}}{\text{CH}}$	H	
11.)	$(\text{CH}_3)_2\text{CHCH}_2\overset{\text{OH}}{\text{CH}}$	H	
12.)	$\triangle\overset{\text{OH}}{\text{CH}}$	H	
13.)	$\text{CF}_3\overset{\text{OH}}{\text{CH}}$	CH ₃	
14.)	$\text{HOCH}_2\overset{\text{OH}}{\text{CH}}$	H	

Ø = phenyl

0037 082

TABLE II (Continued)





Compound	R ⁶	R ⁷	Remarks
15.)	$\text{PNBOCOCH}_2\text{CH}_2$	H	Protected as described for No. 3, Table II, Example 19.
16.)	$\text{CH}_3\text{CH}_2\text{CH}_2\text{CH}(\text{OH})$	H	
17.)	$\text{CH}_3\text{CH}_2\text{CH}(\text{OH})$	H	
18.)	$\text{FCH}_2\text{CH}(\text{OH})$	H	
19.)		H	
20.)	CH_3CH_2	H	
21.)	CH_3	CH_3	
22.)		H	
23.)	$\text{PNBOCOCH}_2\text{CH}_2$	CH_3	Protected as described for No. 3, Table II, Example 18.
24.)		H	
25.)	$\text{N}_3\text{CH}_2\text{CH}(\text{OH})$	H	
25a.)	$\text{ClCH}_2\text{CH}(\text{OH})$	H	
25b.)	$\text{ClCH}_2\text{CH}(\text{OH})$	CH_3	

TABLE II (Continued)

Compound	R ⁶	R ⁷	Remarks
26.)	PNCOCCH_2	H	
27.)	$\text{MeOCH}_2\text{CH}(\text{OH})$	H	
28.)	$\text{CF}_2\text{CH}(\text{OH})$	H	
29.)	PNCOCOCH_2	H	

Example 20

Following the foregoing Examples and text, the following compounds are prepared in representative demonstration of the disclosed process. In the following Table, the resulting compounds are taken from starting materials which are made available by the foregoing text and examples — particularly Table II of Example 19. The column labelled "Remarks and Reagents" annotates the established procedure where necessary to obtain the indicated compound. In most instances the compounds are deblocked according to the procedure described in Example 16. However, when the SR⁸ side chain does not contain a basic function, the final product I is more conveniently isolated as the sodium salt (M=Na); which result is facilitated by conducting the deblocking in a slight excess of NaHCO₃. In any event, when either R⁶ or R⁷ bears a basic group, the final product I is most conveniently isolated as the free acid (M=H), rather than the sodium salt. It should be noted that compounds designated as "free acids" in reality are isolated as inner salts as a consequence of their zwitterionic nature.



M = H, Na

TABLE III

Compound	R ⁶	R ⁷	R ⁸	Remarks, Reagents
1.)	(CH ₃) ₂ CH	H	φ	As in Example 15, but substitute HSφ for HSCH ₂ CH ₂ NHCO ₂ PNB. Deblock as described in Example 16 and isolate product as Na salt. M=Na.
2.)	CH ₃	H	CH ₂ φ	HSCH ₂ φ; M=Na.
3.)	HOCH ₂	CH ₃	CH ₂ CH ₂ CH ₂ NH ₂	HSCH ₂ CH ₂ CH ₂ NHCO ₂ PNB; M = H.
4.)	$\begin{array}{c} \text{OH} \\ \\ \phi\text{CH}_2\text{CH} \end{array}$	H	CH ₂ C(CH ₃) ₂ NH ₂	HSCH ₂ C(CH ₃) ₂ NHCO ₂ PNB; M = H.
5.)	$\begin{array}{c} \text{OH} \\ \\ \text{CH}_3\text{CH} \end{array}$	CH ₃	CH ₂ CH ₂ NH ₂	M = H.
6.)	$\begin{array}{c} \text{OH} \\ \\ \text{CH}_3\text{CH} \end{array}$	$\begin{array}{c} \text{OH} \\ \\ \text{CH}_3\text{CH} \end{array}$	CH ₂ CH ₂ NH ₂	M = H.
7.)	$\begin{array}{c} \text{OH} \\ \\ \text{CH}_3\text{CH} \end{array}$	φCH ₂	CH ₂ CH ₂ N(CH ₃) ₂	HSCH ₂ CH ₂ N(CH ₃) ₂ ; M = H.
8.)	$\begin{array}{c} \text{NH}_2 \\ \\ \text{CH}_3\text{CH} \end{array}$	H	CH ₂ CH ₂ NH ₂	M = H.
9.)	$\begin{array}{c} \text{OH} \\ \\ (\text{CH}_3)_2\text{CHCH} \end{array}$	H	$\begin{array}{c} \text{CH}_2 \\ \\ \text{N} \quad \text{N} \\ \diagup \quad \diagdown \\ \text{H} \end{array}$	$\begin{array}{c} \text{HSCH}_2 \\ \\ \text{N} \quad \text{N} \\ \diagup \quad \diagdown \\ \text{H} \end{array}$; M = Na

φ = phenyl

89

0037 082

TABLE III (Continued)





Compound	R ⁶	R ⁷	R ⁸	Remarks, Reagents
10.)	$\begin{array}{c} \text{OH} \\ \\ (\text{CH}_3)_2\text{CHCH}_2\text{CH}_2\text{CH} \end{array}$	H		 : M = H
11.)		H		 : M = H
12.)	$\begin{array}{c} \text{OH} \\ \\ \text{CF}_3\text{CH} \end{array}$	H	CH ₂ CH ₂ NH ₂	M = H.
13.)	$\begin{array}{c} \text{OH} \\ \\ \text{HOCH}_2\text{CH} \end{array}$	H	CH ₂ CH ₂ NH ₂	M = H.
14.)	HOCH ₂ CH ₂	H		 : M = H
14a.)	$\begin{array}{c} \text{OH} \\ \\ \text{CH}_2=\text{CH}-\text{CH} \end{array}$	H	CH ₂ CH ₂ NH ₂	M = H.

TABLE III (Continued)







Compound	R ⁶	R ⁷	R ⁸	Remarks, Reagents
15.)	$\text{CH}_3\text{CH}_2\text{CH}_2\text{CH}(\text{OH})\text{CH}_3$	H		 ; M = H
16.)	$\text{CH}_3\text{CH}_2\text{CH}(\text{OH})\text{CH}_3$	H		 ; M = H
17.)	$\text{FCH}_2\text{CH}(\text{OH})\text{CH}_3$	H	$\text{CH}_2\text{CH}_2\text{NH}_2$	
18.)	 -CH ₂ CH(OH)CH ₃	H	$\text{CH}_2\text{CH}_2\text{CO}_2\text{H}$	$\text{HSCH}_2\text{CH}_2\text{CO}_2\text{PNB}$; Product isolated as disodium salt.
19.)	$\text{CH}_3\text{CH}_2\text{CH}_2$	H	$\text{CH}_2\text{CH}_2\text{NH}_2$	
20.)	CH_3	CH_3		 ; M = Na
21.)		H	$\text{CH}_2\text{CH}_2\text{OH}$	$\text{HSCH}_2\text{CH}_2\text{OH}$; M = Na.

TABLE III (Continued)




Compound	R ⁶	R ⁷	R ⁸	Remarks, Reagents
22.)	HOCH ₂ CH ₂ OH	CH ₃	CH ₂ CH ₂ CH ₂ CH ₂ NH ₂	HSCH ₂ CH ₂ CH ₂ CH ₂ NHO ₂ PNB; M = H.
23.)		H	CH ₂ C(CH ₃) ₂ CH ₂ NH ₂	CH ₂ C(CH ₃) ₂ CH ₂ NHCO ₂ PNB; M = H.
24.)		H	CH ₂ CH ₂ NH ₂	M = Na.
25.)		H	CH ₂ CH ₂ NH ₂	M = Na.
26.)	OH CH ₃ CH	H		 ; M = Na
27.)	"	H		 ; M = Na
28.)	"	H		 NHCO ₂ PNB; M = H

TABLE III (Continued)

Compound	R ⁶	R ⁷	R ⁸	Remarks, Reagents
29.)		H		; M = Na
30.)	"	H		; M = H
31.)	"	H		; M = H
32.)	"	H		; M = H
33.)	"	H		; M = H.
34.)	"	H		; M = H
35.)	"	H		; M = H
36.)	"	H		; M = H

TABLE III (Continued)

Compound	R ⁶	R ⁷	R ⁸	Remarks, Reagents
37.)		H		
38.)	"	H		
39.)	"	H		
40.)	"	H		
41.)	"	H		
42.)	"	H		
43.)	"	H		
44.)	"	H		







TABLE III (Continued)

Compound	R ⁶	R ⁷	R ⁸	Remarks, Reagents
45.)		H		; M = H
46.)	"	H		M = Na.
47.)	"	H		M = Na.
48.)	"	H		M = H.
49.)	"	H		M = H.
50.)	"	H		; M = H
51.)	"	H		M = Na.

69

0037 082

TABLE III (Continued)

Compound	R ⁶	R ⁷	R ⁸	Remarks, Reagents
52.)	$\begin{array}{c} \text{OH} \\ \\ \text{CH}_3\text{CH} \end{array}$	H		 M = H
53.)	"	H		M = H
54.)	"	H		M = H
55.)	"	H		 ; M = H
56.)	"	H		 M = H
57.)	"	H		 M = H

Compounds


58-89	Compounds 58-89 correspond sequentially to compounds 26-57, above, except that the value for R^6 is taken as CH_3CH_2 rather than the $\text{CH}_3\text{C}(\text{OH})\text{H}$ of Compounds 26-57.
90-121	Compounds 90-121 correspond sequentially to compounds 26-57, above, except that the value for R^6 is taken as Cl_2CHCH rather than the $\text{CH}_3\text{C}(\text{OH})\text{H}$ of Compounds 26-57. $\begin{array}{c} \text{OH} \\ \\ \text{Cl}_2\text{CHCH} \end{array}$
122-153	Compounds 122-153 correspond sequentially to compounds 26-57, above, except that the value for R^6 is taken as CF_3CH rather than the $\text{CH}_3\text{C}(\text{OH})\text{H}$ of Compounds 26-57.. $\begin{array}{c} \text{OH} \\ \\ \text{CF}_3\text{CH} \end{array}$
154-185	Compounds 154-185 correspond sequentially to compounds 26-57, above, except that the value for R^6 is taken as HOCH_2CH rather than the $\text{CH}_3\text{C}(\text{OH})\text{H}$ of Compounds 26-57. $\begin{array}{c} \text{OH} \\ \\ \text{HOCH}_2\text{CH} \end{array}$
186-217	Compounds 186-217 correspond sequentially to compounds 26-57, above, except that the value for R^6 is taken as ClCH_2CH rather than the $\text{CH}_3\text{C}(\text{OH})\text{H}$ of Compounds 26-57. $\begin{array}{c} \text{OH} \\ \\ \text{ClCH}_2\text{CH} \end{array}$
218-249	Compounds 218-249 correspond sequentially to compounds 26-57, above, except that the value for R^6 is taken as $\text{CH}_3\text{CH}_2\text{CH}$ rather than the $\text{CH}_3\text{C}(\text{OH})\text{H}$ of Compounds 26-57. $\begin{array}{c} \text{OH} \\ \\ \text{CH}_3\text{CH}_2\text{CH} \end{array}$
250-281	Compounds 250-281 correspond sequentially to compounds 26-57, above, except that the value for R^6 is taken as  rather than the $\text{CH}_3\text{C}(\text{OH})\text{H}$ of Compounds 26-57. $\begin{array}{c} \text{OH} \\ \\ \text{---CH} \end{array}$
282-313	Compounds 282-313 correspond sequentially to compounds 26-57, above, except that the value for R^6 is taken as $\text{H}_2\text{NCH}_2\text{CH}$ rather than the $\text{CH}_3\text{C}(\text{OH})\text{H}$ of Compounds 26-57. $\begin{array}{c} \text{OH} \\ \\ \text{H}_2\text{NCH}_2\text{CH} \end{array}$
314-345	Compounds 314-345 correspond sequentially to compounds 26-57, above, except that the value for R^6 is taken as $\text{CF}_2\text{HC-}$ rather than the $\text{CH}_3\text{C}(\text{OH})\text{H}$ of Compounds 26-57. $\begin{array}{c} \text{OH} \\ \\ \text{CF}_2\text{HC-} \end{array}$
346-377	Compounds 346-377 correspond sequentially to compounds 26-57, above, except that the value for R^6 is taken as HOCH_2 rather than the $\text{CH}_3\text{C}(\text{OH})\text{H}$ of Compounds 26-57.
378-409	Compounds 378-409 correspond sequentially to compounds 26-57, above, except that the value for R^6 is taken as HO_2CCH_2 rather than the $\text{CH}_3\text{C}(\text{OH})\text{H}$ of Compounds 26-57.

Compounds

- 410-441 Compounds 410-441 correspond sequentially to compounds
26-57, above, except that the value for R^6 is taken as CH_3OCH_2CH
rather than the $CH_3C(OH)H$ of Compounds 26-57.
- 442-473 Compounds 442-473 correspond sequentially to compounds
26-57, above, except that the value for R^6 is taken as $(CH_3)_3CCH_2CH$
rather than the $CH_3C(OH)H$ of Compounds 26-57.

Claims

1. A compound having the structure



wherein $R^{1'}$ is hydrogen or a readily removable known protecting group; R^a and R^b are independently selected from: alkyl having 1-6 carbon atoms, phenyl, trityl, benzyl, methoxybenzyl, ethoxybenzyl and $-(CH_2)_3-$ (joinder of R^a and R^b); R^c is alkyl having 1-6 carbon atoms, or phenyl; and wherein R^6 and R^7 are independently selected from the group consisting of: hydrogen; substituted and unsubstituted: alkyl, alkenyl, and alkynyl, having from 1-10 carbon atoms; cycloalkyl, cycloalkylalkyl, and alkylcycloalkyl having 3-6 carbon atoms in the cycloalkyl ring and 1-6 carbon atoms in the alkyl moieties; phenyl; aralkyl, aralkenyl, and aralkynyl wherein the aryl moiety is phenyl and the aliphatic portion has 1-6 carbon atoms; wherein the substituent or substituents relative to the above named radicals are selected from the group consisting of:

chloro, bromo, fluoro, R^1 ,

$-OH$,

$-OR^1$,

$-OC(=O)NR^1R^2$,

$-C(=O)NR^1R^2$,

$-NR^1R^2$,

$-NH_2$,

$-NHR^1$,




Compounds

- 410-441 Compounds 410-441 correspond sequentially to compounds $\text{CH}_3\text{OCH}_2\text{CH}(\text{OH})\text{CH}_3$
- 26-57, above, except that the value for R^6 is taken as rather than the $\text{CH}_3\text{C}(\text{OH})\text{H}$ of Compounds 26-57.
- 442-473 Compounds 442-473 correspond sequentially to compounds $(\text{CH}_3)_3\text{CCH}_2\text{CH}(\text{OH})\text{CH}_3$
- 26-57, above, except that the value for R^6 is taken as rather than the $\text{CH}_3\text{C}(\text{OH})\text{H}$ of Compounds 26-57.

Claims

1. A compound having the structure



wherein $\text{R}^{1'}$ is hydrogen or a readily removable known protecting group; R^a and R^b are independently selected from: alkyl having 1-6 carbon atoms, phenyl, trityl, benzyl, methoxybenzyl, ethoxybenzyl and $-(\text{CH}_2)_3-$ (joinder of R^a and R^b); R^c is alkyl having 1-6 carbon atoms, or phenyl; and wherein R^6 and R^7 are independently selected from the group consisting of: hydrogen; substituted and unsubstituted: alkyl, alkenyl, and alkynyl, having from 1-10 carbon atoms; cycloalkyl, cycloalkylalkyl, and alkylcycloalkyl having 3-6 carbon atoms in the cycloalkyl ring and 1-6 carbon atoms in the alkyl moieties; phenyl; aralkyl, aralkenyl, and aralkynyl wherein the aryl moiety is phenyl and the aliphatic portion has 1-6 carbon atoms; wherein the substituent or substituents relative to the above named radicals are selected from the group consisting of:

chloro, bromo, fluoro, R^1 ,

$-\text{OH}$,

$-\text{OR}^1$,

$-\text{OCN}(\text{R}^1)\text{R}^2$,

$-\text{CN}(\text{R}^1)\text{R}^2$,


$-\text{NR}^1\text{R}^2$,

$-\text{NH}_2$,


$-\text{NHR}^1$,




68




5





10




15




20



25




30




35



40



45



50



55 wherein, relative to the above listed substituents on R^6 , and R^7 , the groups R^1 and R^2 are independently selected from: hydrogen, alkyl, alkenyl, and alkynyl, having from 1—10 carbon atoms; cycloalkyl, cycloalkylalkyl, and alkylcycloalkyl, having 3—6 carbon atoms in the cycloalkyl ring and 1—6 carbon atoms in the alkyl moieties; phenyl, aralkyl, aralkenyl, and aralkynyl wherein the aryl moiety is phenyl and the aliphatic portion has 1—6 carbon atoms; R^6 and R^7 are not both hydrogen at the same time; when R^6/R^7 is hydrogen, 60 then R^7/R^6 is not

65




or





0037082

2. A compound having the structure



wherein R^{1'}, R^c, R⁶ and R⁷ are as defined in Claim 1.

3. A compound according to Claims 1 or 2 wherein R^{1'} is hydrogen or a triorganosilyl group.

4. A compound according to Claim 3 wherein R^{1'} is hydrogen or a trialkylsilyl group wherein each alkyl moiety has from 1—6 carbon atoms; R^c is alkyl having 1—3 carbon atoms, phenyl; and R^a and R^b are: —(CH₂)₃—, or alkyl having 1—3 carbon atoms each.

5. A compound according to Claims 1, 2, 3 or 4 wherein R⁶ and R⁷ are independently selected from the group consisting of: hydrogen; substituted and unsubstituted: alkyl, alkenyl and alkynyl having from 1—10 carbon atoms, cycloalkyl, cycloalkylalkyl and alkylcycloalkyl, having 3—6 carbon atoms in the cycloalkyl ring and 1—6 carbon atoms in the alkyl moieties; phenyl; aralkyl, aralkenyl, and aralkynyl wherein the aryl moiety is phenyl and the aliphatic portion has 1—6 carbon atoms; wherein the substituent or substituents relative to the above named radicals are selected from the group consisting of:

chloro, bromo, fluoro,

—OH ,






—OR¹ ,

—NR¹R² ,

—NH₂ ,

—NHR¹ ,

—SO₂NR¹R² ,



wherein, relative to the above listed substituents on R^6 , and R^7 , the groups R^1 and R^2 are independently selected from: hydrogen, alkyl, alkenyl and alkynyl, having from 1—10 carbon atoms; cycloalkyl, cycloalkylalkyl, and alkylcycloalkyl, having 3—6 carbon atoms in the cycloalkyl ring and 1—6 carbon atoms in the alkyl moieties, phenyl; aralkyl, aralkenyl, and aralkynyl wherein the aryl moiety is phenyl and the aliphatic portion has 1—6 carbon atoms.


6. A compound according to Claims 1, 2, 3, 4 or 5 wherein R^7 is hydrogen or methyl.

7. A compound according to Claim 6 wherein R^6 is selected from the group consisting of: substituted and unsubstituted: alkyl, alkenyl and cycloalkylalkyl wherein the substituent or substituents are selected from hydroxyl, alkoxyl having from 1—6 carbon atoms, phenoxy, amino, and carboxy.

8. A compound according to Claims 6 or 7 wherein R^6 is selected from the group consisting of alkyl, cycloalkylalkyl, alkyl substituted by one or more hydroxyl groups, or cycloalkylalkyl substituted by one or more hydroxyl groups.

9. A compound according to Claims 6, 7 or 8 wherein R^7 is hydrogen.


10. A process for preparing a compound according to Claims 1, 2, 3, 4, 5, 6, 7, 8 or 9 having the structure:






0 037 082


which comprises the steps of treating:



with :




wherein M is a metal cation to yield:




followed by treating in the presence of base with a known alkylating or acylating agent calculated to establish R⁶ and R⁷.

11. A process for preparing a compound according to Claims 1, 2, 3, 4, 5, 6, 7, 8 or 9 having the structure:



comprising treating a compound according to Claim 10 with a Lewis acid.

12. A process for preparing:




comprising the step of treating a compound of Claim 11 with a known oxidizing agent.




0037082

13. A compound according to Claim 1 or 2 wherein R^7 is hydrogen and R^6 is selected from the group consisting of:


5




10




15




20




25




30




35



40




45



14. A process for preparing

50



55

and the pharmaceutically acceptable salt, ester and amide derivatives thereof; wherein: R^6 , R^7 are defined as in Clai 1 and R^8 is selected from hydrogen; substituted and unsubstituted: alkyl, alkenyl, and alkynyl, having from 1—10 carbon atoms; cycloalkyl, cycloalkylalkyl, and alkylcycloalkyl, having 3—6 carbon atoms in the cycloalkyl ring and 1—6 carbon atoms in the alkyl moieties; phenyl; aralkyl, aralkenyl, and aralkynyl wherein the aryl moiety is phenyl and the aliphatic portion has 1—6 carbon atoms; heteroaryl, heteroaralkyl, heterocyclyl and heterocyclylalkyl wherein the heteroaryl moiety or the heterocyclyl moiety has 5 or 6 ring members containing 1—4 O, N or S atoms and the alkyl moieties have 1 to 6 carbon atoms;



0037082

wherein the substituent or substituents relative to the above-named radicals are selected from the group consisting of:

5 $-X^o$ halo (chloro, bromo, fluoro),

$-OH$,

$-OR^1$,

10 $\begin{array}{c} O \\ || \\ -OCNR^1R^2 \end{array}$,

15 $\begin{array}{c} O \\ || \\ -CNR^1R^2 \end{array}$,

$-NR^1R^2$,

$-NH_2$,

20 $-NHR^1$,

25 $\begin{array}{c} NR^1 \\ \diagup \\ NR^1R^2 \end{array}$,

$-SO_2NR^1R^2$,

30 $\begin{array}{c} O \\ | \\ -NHCNR^1R^2 \end{array}$,

35 $\begin{array}{c} O \\ || \\ -R^2NCR^1 \end{array}$,

$-CO_2H$,

$-CO_2R^1$,

40 $\begin{array}{c} O \\ || \\ -CR^1 \end{array}$,

45 $\begin{array}{c} O \\ || \\ -OCR^1 \end{array}$,

$-SH$,

50 $\begin{array}{c} O \\ || \\ -SR^1 \end{array}$,

55 $\begin{array}{c} O \\ || \\ -SR^1 \\ || \\ O \end{array}$,

$-CN$, and


60 $-N_3$

wherein the groups R^1 and R^2 are independently selected from: hydrogen, alkyl, alkenyl, and alkynyl, having from 1—10 carbon atoms; cycloalkyl, cycloalkylalkyl, and alkylcycloalkyl, having 3—6 carbon atoms in the cycloalkyl ring and 1—6 carbon atoms in the alkyl moieties; phenyl; aralkyl, aralkenyl, and aralkynyl wherein the aryl moiety is phenyl and the aliphatic portion has 1—6 carbon atoms; heteroaryl,




0 037 082


heteroaralkyl, heterocyclyl and heterocyclalkyl; wherein the hetero aryl moiety or the heterocyclyl moiety has 5 or 6 ring members containing 1—4 atoms selected independently from oxygen, nitrogen or sulphur and wherein the alkyl moieties associated with said heterocyclic moieties have 1—6 carbon atoms; or wherein R^8 is the group $-(CH_2)_nX(CH_2)_mR^9$ wherein $n=2$ to 4, $m=2$ to 4, $X=NR^0$, O or S; wherein R^0 is H, CH_3 , CH_2CH_3 , CH_2CH_2OH or $CH_2CH_2NA_2$ and R^9 is OH, NH_2 , $NHCH_{31}$, $N(CH_3)_2$,




which process comprises the steps of oxidizing:



to form:




wherein $R^{1'}$ is hydrogen or a known protecting group; and R^C is independently selected from alkyl having 1—6 carbon atoms and phenyl; followed by treating with 1,1'-carbonyldimidazole followed by $(R^{2'}O_2CCH_2CO_2)_2Mg$ to yield:



wherein $R^{2'}$ is a known protecting group or a pharmaceutically acceptable ester moiety; followed by diazotizing, cyclizing, activating and reacting with HSR^8 .

Patentansprüche

1. Verbindung mit der Struktur



worin R^1 Wasserstoff oder eine leicht entfernbare bekannte Schutzgruppe ist; R^a und R^b unabhängig ausgewählt sind aus: Alkyl mit 1—6 Kohlenstoffatomen, Phenyl, Trityl, Benzyl, Methoxybenzyl, Ethoxybenzyl und $-(CH_2)_3-$ (Verbindung von R^a und R^b); R^C Alkyl mit 1—6 Kohlenstoffatomen oder Phenyl ist; und worin R^6 und R^7 unabhängig ausgewählt sind aus der Gruppe von: Wasserstoff; substituiertem und unsubstituiertem: Alkyl, Alkenyl und Alkynyl, mit 1—10 Kohlenstoffatomen; Cycloalkyl, Cycloalkylalkyl und Alkylcycloalkyl mit 3—6 Kohlenstoffatomen im Cycloalkylring und 1—6 Kohlenstoffatomen in den Alkylresten; Phenyl; Arylalkyl, Arylalkenyl und Arylalkinyl, worin der Arylrest Phenyl ist und der aliphatische Teil



0 037 082

1—6 Kohlenstoffatome hat; worin der Substituent oder die Substituenten der vorstehend aufgeführten Reste ausgewählt sind aus der Gruppe von:

Chlor, Brom, Fluor, R¹,

—OH ,

—OR¹ ,

$\begin{array}{c} \text{O} \\ \parallel \\ \text{—OCNR}^1\text{R}^2 \end{array}$,

$\begin{array}{c} \text{O} \\ \parallel \\ \text{—CNR}^1\text{R}^2 \end{array}$,

—NR¹R² ,

—NH₂ ,

—NHR¹ ,

$\begin{array}{c} \text{NR}^1 \\ \diagup \\ \diagdown \\ \text{NR}^1\text{R}^2 \end{array}$,

—SO₂NR¹R² ,

$\begin{array}{c} \text{O} \\ \parallel \\ \text{—NHCNR}^1\text{R}^2 \end{array}$,

$\begin{array}{c} \text{O} \\ \parallel \\ \text{—R}^2\text{NCR}^1 \end{array}$,

—CO₂H ,

—CO₂R¹ ,

$\begin{array}{c} \text{O} \\ \parallel \\ \text{—CR}^1 \end{array}$,

$\begin{array}{c} \text{O} \\ \parallel \\ \text{—OCR}^1 \end{array}$,

—SH ,

$\begin{array}{c} \text{O} \\ \parallel \\ \text{—SR}^1 \end{array}$,

$\begin{array}{c} \text{O} \\ \parallel \\ \text{—SR}^1 \\ \parallel \\ \text{O} \end{array}$,

—CN , und

—N₃


worin, bezogen auf die vorstehend aufgelisteten Substituenten an R⁶ und R⁷ die Gruppen R¹ und R² unabhängig ausgewählt sind aus: Wasserstoff, Alkyl, Alkenyl und Alkinyll, mit 1—10 Kohlenstoffatomen;




76

0037082

Cycloalkyl, Cycloalkylalkyl und Alkylcycloalkyl, mit 3—6 Kohlenstoffatomen in dem Cycloalkylring und 1—6 Kohlenstoffatomen in den Alkylresten; Phenyl, Aralkyl, Aralkenyl und Aralkinyl, worin der Arylrest Phenyl ist und der aliphatische Teil 1—6 Kohlenstoffatome hat; wobei R⁶ und R⁷ nicht beide gleichzeitig Wasserstoff sind; wenn R⁶/R⁷ Wasserstoff ist, dann ist



2. Verbindung mit der Struktur



worin R¹, R⁶, R⁶ und R⁷ wie in Anspruch 1 definiert sind.

3. Verbindung nach den Ansprüchen 1 oder 2, worin R¹ Wasserstoff oder eine Triorganosilylgruppe ist.

4. Verbindung nach Anspruch 3, worin R¹ Wasserstoff oder eine Trialkylsilylgruppe ist, worin jeder Alkylrest 1—6 Kohlenstoffatome hat; R⁶ Alkyl mit 1—3 Kohlenstoffatomen, Phenyl ist; und R⁶ und R⁶ sind: —(CH₂)₃—, oder Alkyl mit jeweils 1—3 Kohlenstoffatomen.


5. Verbindung nach Anspruch 1, 2, 3 oder 4, worin R⁶ und R⁷ unabhängig ausgewählt sind aus der Gruppe von: Wasserstoff; substituiertem und unsubstituiertem: Alkyl, Alkenyl und Alkinyl mit 1—10 Kohlenstoffatomen, Cycloalkyl, Cycloalkylalkyl und Alkylcycloalkyl, mit 3—6 Kohlenstoffatomen im Cycloalkylring und 1—6 Kohlenstoffatomen in den Alkylresten; Phenyl; Aralkyl, Aralkenyl und Aralkinyl, worin der Arylrest Phenyl ist und der aliphatische Teil 1—6 Kohlenstoffatome hat; worin der Substituent und die Substituenten bezüglich der vorstehend genannten Reste ausgewählt sind aus der Gruppe von:

Chlor, Brom, Fluor,

—OH,

—OR¹,


 ,

 ,

—NR¹R²,

—NH₂,

—NHR¹,








 ,

—SO₂NR¹R²,



* C L M S *

0037082



worin, bezogen auf die vorstehend aufgelisteten Substituenten an R^6 und R^7 , die Gruppen R^1 und R^2 unabhängig ausgewählt sind aus: Wasserstoff, Alkyl, Alkenyl und Alkynyl, mit 1—10 Kohlenstoffatomen; Cycloalkyl, Cycloalkylalkyl und Alkylcycloalkyl, mit 3—6 Kohlenstoffatomen in dem Cycloalkylring und 1—6 Kohlenstoffatomen in den Alkylresten, Phenyl; Aralkyl, Aralkenyl und Aralkinyl, worin der Arylrest Phenyl ist und der aliphatische Teil 1—6 Kohlenstoffatome hat.


6. Verbindung nach den Ansprüchen 1, 2, 3, 4 oder 5, worin R^7 Wasserstoff oder Methyl ist.

7. Verbindung nach Anspruch 6, worin R^6 ausgewählt ist aus der Gruppe von: substituiertem und unsubstituiertem: Alkyl, Alkenyl und Cycloalkylalkyl, worin der Substituent oder die Substituenten ausgewählt sind aus Hydroxyl, Alkoxyl mit 1—6 Kohlenstoffatomen, Phenoxy, Amino und Carboxy.

8. Verbindung nach den Ansprüchen 6 oder 7, worin R^6 ausgewählt ist aus der Gruppe von Alkyl, Cycloalkylalkyl, Alkyl substituiert durch eine oder mehrere Hydroxylgruppen, oder Cycloalkylalkyl substituiert durch eine oder mehrere Hydroxylgruppen.

9. Verbindung nach den Ansprüchen 6, 7 oder 8, worin R^7 Wasserstoff ist.


10. Verfahren zur Herstellung einer Verbindung nach den Ansprüchen 1, 2, 3, 4, 5, 6, 7, 8 oder 9 mit der Struktur






0037082


das die Stufen umfaßt der Behandlung von:



10 mit:




20 worin M ein Metallkation ist unter Bildung von:




30 gefolgt von der Behandlung in der Anwesenheit einer Base mit einem bekannten Alkylierungs- oder Acylierungsmittel, das so bestimmt ist, daß R⁶ und R⁷ ausgebildet werden.

35 11. Verfahren zur Herstellung einer Verbindung nach den Ansprüchen 1, 2, 3, 4, 5, 6, 7, 8 oder 9 mit der Struktur



45 durch Behandeln einer Verbindung nach Anspruch 10 mit einer Lewissäure.

50 12. Verfahren zur Herstellung von













60 das die Stufe der Behandlung einer Verbindung nach Anspruch 11 mit einem bekannten Oxidationsmittel umfaßt.




0037 082

13. Verbindung nach Anspruch 1 oder 2, worin R⁷ Wasserstoff ist und R⁶ ausgewählt ist aus der Gruppe von:



14. Verfahren zur Herstellung von



55 und der pharmazeutisch brauchbaren Salz-, Ester- und Amidderivate davon; worin R⁶, R⁷ wie in Anspruch 1 definiert sind und R⁸ ausgewählt ist aus Wasserstoff; substituiertem und unsubstituiertem: Alkyl, Alkenyl und Alkynyl, mit 1—10 Kohlenstoffatomen; Cycloalkyl, Cycloalkylalkyl und Alkylcycloalkyl, mit 3—6 Kohlenstoffatomen im Cycloalkylring und 1—6 Kohlenstoffatomen in den Alkylresten; Phenyl; Aralkyl, Aralkenyl und Aralkinyl, worin der Arylrest Phenyl ist und der aliphatische Teil 1—6 Kohlenstoffatome hat; Heteroaryl, Heteroaralkyl, Heterocyclyl und Heterocyclalkyl, worin der Heteroarylrest oder der Heterocyclylrest 5 oder 6 Ringglieder, die 1—4 O-, N- oder S-Atome enthalten, hat und die Alkylreste 1 bis 6 Kohlenstoffatome



0037082

haben; worin der Substituent oder die Substituenten bezüglich der vorstehend genannten Reste ausgewählt sind aus der Gruppe von:

5

 $-X^{\circ}$ Halogen (Chlor, Brom, Fluor), $-OH$, $-OR^1$,

10

$$\begin{array}{c} O \\ || \\ -OCNR^1R^2 \end{array},$$

15

$$\begin{array}{c} O \\ || \\ -CNR^1R^2 \end{array},$$
 $-NR^1R^2$, $-NH_2$,

20

 $-NHR^1$,

25

$$\begin{array}{c} NR^1 \\ \diagup \\ \diagdown \\ NR^1R^2 \end{array},$$
 $-SO_2NR^1R^2$,

30

$$\begin{array}{c} O \\ || \\ -NHCNR^1R^2 \end{array},$$

35

$$\begin{array}{c} O \\ || \\ -R^2NCR^1 \end{array},$$
 $-CO_2H$, $-CO_2R^1$,

40

$$\begin{array}{c} O \\ || \\ -CR^1 \end{array},$$

45

$$\begin{array}{c} O \\ || \\ -OCR^1 \end{array},$$
 $-SH$,

50

$$\begin{array}{c} O \\ || \\ -SR^1 \end{array},$$

55

$$\begin{array}{c} O \\ || \\ -SR^1 \\ || \\ O \end{array},$$
 $-CN$, und

60

 $-N_3$

65 worin die Gruppen R^1 und R^2 unabhängig ausgewählt sind aus: Wasserstoff, Alkyl, Alkenyl und Alkynyl mit 1—10 Kohlenstoffatomen; Cycloalkyl, Cycloalkylalkyl und Alkylcycloalkyl, mit 3—6 Kohlenstoffatomen in dem Cycloalkylring und 1—6 Kohlenstoffatomen in den Alkylresten; Phenyl, Arylalkyl, Arylalkenyl und




0037 082

Aralkinyl, worin der Arylrest Phenyl ist und der aliphatische Teil 1—6 Kohlenstoffatome hat; Heteroaryl, Heteroaralkyl, Heterocyclyl und Heterocyclylalkyl; worin der Heteroarylrest oder der Heterocyclylrest 5 oder 6 Ringglieder hat, die 1—4 Atome enthalten, die unabhängig ausgewählt sind aus Sauerstoff, Stickstoff oder Schwefel, und worin die Alkylreste, die mit diesen heterocyclischen Resten verbunden sind, 1—6 Kohlenstoffatome haben; oder worin R^8 die Gruppe $-(CH_2)_nX(CH_2)_mR^9$ ist, worin $n=2$ bis 4, $m=2$ bis 4, $X=NR$, O oder S; worin R^9 H, CH_3 , CH_2CH_3 , CH_2CH_2OH oder $CH_2CH_2NH_2$ ist und R^9 OH, NH_2 , $NHCH_3$, $N(CH_3)_2$,

10




15



ist; wobei das Verfahren die Stufen umfaßt der der Oxidation von:


20



25

unter Bildung von


30



35

worin $R^{1'}$ Wasserstoff oder eine bekannte Schutzgruppe ist; und R^c unabhängig ausgewählt ist aus Alkyl mit 1—6 Kohlenstoffatomen und Phenyl; gefolgt von der Behandlung mit 1,1'-Carbonyldimidazol, gefolgt von $(R^{2'}O_2CCH_2CO_2)_2Mg$ unter Bildung von

40



45


worin $R^{2'}$ eine bekannte Schutzgruppe oder ein pharmazeutisch brauchbarer Esterrest ist; gefolgt von dem Diazotieren, Cyclisieren, Aktivieren und der Reaktion mit HSR^a .

Revendications

50

1. Composé possédant la structure

55



60

dans laquelle $R^{1'}$ est l'hydrogène ou un groupe protecteur connu facilement éliminable; R^a et R^b sont indépendamment choisis parmi les groupes: alkyle ayant 1 à 6 atomes de carbone, phényle, trityle, benzyle, méthoxybenzyle, éthoxybenzyle et $-(CH_2)_3-$ (reliant R^a et R^b); R^c est un groupe alkyle ayant 1 à 6 atomes de carbone ou phényle; et dans lesquelles R^6 et R^7 sont choisis indépendamment dans le groupe constitué par: l'hydrogène; les groupes substitués et non substitués: alkyle, alcényle et alcynyle ayant de 1 à 10 atomes de carbone; cycloalkyle, cycloalkylalkyle et alkylcycloalkyle ayant 3 à 6 atomes de carbone

65

dans le cycle cycloalkyle et 1 à 6 atomes de carbone dans les restes alkyle; phényle, arylalkyle, arylalcényle



0037082

et arylalcynyle dans lesquels le reste aryle est le phényle et la partie aliphatique possède 1 à 6 atomes de carbone; dans lesquelles le ou les substituants concernant les radicaux sus-nommés sont choisis dans le groupe constitué par:

chloro, bromo, fluoro, R^1

$-\text{OH}$,

$-\text{OR}^1$,

$-\text{O}=\text{C}-\text{NR}^1\text{R}^2$,

$-\text{C}=\text{O}-\text{NR}^1\text{R}^2$,

$-\text{NR}^1\text{R}^2$,

$-\text{NH}_2$,

$-\text{NHR}^1$,

$-\text{C}(\text{NR}^1)(\text{NR}^1\text{R}^2)-$,

$-\text{SO}_2\text{NR}^1\text{R}^2$,

$-\text{NH}-\text{C}(=\text{O})-\text{NR}^1\text{R}^2$,

$-\text{R}^2-\text{C}(=\text{O})-\text{NR}^1$,

$-\text{CO}_2\text{H}$,

$-\text{CO}_2\text{R}^1$,

$-\text{C}(=\text{O})-\text{R}^1$,

$-\text{O}-\text{C}(=\text{O})-\text{R}^1$,

$-\text{SH}$,

$-\text{S}-\text{R}^1$,

$-\text{S}(=\text{O})_2-\text{R}^1$,

$-\text{CN}$, et


$-\text{N}_3$

dans lesquels, en ce qui concerne les substituants sur R^6 et R^7 dont la liste figure ci-dessus, les groupes R^1 et R^2 sont choisis indépendamment parmi: l'hydrogène, les groupes alkyle, alcényle et alcynyle ayant de 1




0 037 082

à 10 atomes de carbone; cycloalkyle, cycloalkylalkyle et alkylcycloalkyle ayant 3 à 6 atomes de carbone dans le cycle cycloalkyle et 1 à 6 atomes de carbone dans les restes alkyle; phényle, arylalkyle, arylalcényle et arylalcynyle dans lesquels le reste aryle est le phényle et la partie aliphatique possède 1 à 6 atomes de carbone; R^6 et R^7 ne sont pas tous deux en même temps l'hydrogène; lorsque R^6/R^7 est l'hydrogène, alors



2. Composé possédant la structure



dans laquelle R^1 , R^c , R^6 et R^7 sont tels que définis dans la revendication 1.

3. Composé selon les revendications 1 ou 2, caractérisé en ce que R^1 est l'hydrogène ou un groupe triorganosilyle.

4. Composé selon la revendication 3, caractérisé en ce que R^1 est l'hydrogène ou un groupe trialkylsilyle dans lequel chaque reste alkyle possède de 1 à 6 atomes de carbone; R^c est un groupe alkyle ayant 1-3 atomes de carbone, un groupe phényle; et R^6 et R^7 sont: $-(CH_2)_3-$ ou alkyle ayant chacun 1-3 atomes de carbone.

5. Composé selon les revendications 1, 2, 3 ou 4, caractérisé en ce R^6 et R^7 sont choisis indépendamment dans le groupe constitué par l'hydrogène, les groupes substitués et non substitués: alkyle, alcényle et alcynyle ayant de 1 à 10 atomes de carbone; cycloalkyle, cycloalkylalkyle et alkylcycloalkyle ayant 3 à 6 atomes de carbone dans le cycle cycloalkyle et 1 à 6 atomes de carbone dans les restes alkyle; phényle; arylalkyle, arylalcényle et arylalcynyle dans lesquels le rest aryle le phényle et la partie aliphatique possède 1 à 6 atomes de carbone; dans laquelle le ou les substituants relatifs aux radicaux mentionnés ci-dessus sont choisis dans le groupe constitué par:

chloro, bromo, fluoro,

$-OH$,

$-OR^1$,

$-OC(=O)NR^1R^2$,

$-C(=O)NR^1R^2$,

$-NR^1R^2$,

$-NH_2$,

$-NHR^1$,

$-C(=NR^1)(NR^1R^2)-$,

$-SO_2NR^1R^2$,





0 037 082

84


5




10



15




20



25



30



35



40

dans lesquels, en ce qui concerne les substituants sur R^6 et R^7 dont la liste figure ci-dessus, les groupes R^1 et R^2 sont choisis indépendamment parmi: l'hydrogène, les groupes alkyle, alcényle et alcynyle ayant de 1 à 10 atomes de carbone; cycloalkyle, cycloalkylalkyle et alkylcycloalkyle ayant 3 à 6 atomes de carbone dans le cycle cycloalkyle et 1 à 6 atomes de carbone dans les restes alkyle; phényle; arylalkyle, arylalcényle et arylalcynyle dans lesquels le reste aryle est le phényle et la partie aliphatique possède 1 à 6 atomes de carbone.

45

6. Composé selon les revendications 1, 2, 3, 4 ou 5, caractérisé en ce que R^7 est l'hydrogène ou le méthyle.

50

7. Composé selon la revendication 6, caractérisé en ce que R^6 est choisi dans le groupe constitué par les groupes substitués ou non substitués: alkyle, alcényle et cycloalkyle dans lesquels le ou les substituants sont choisis parmi les groupes hydroxyle, alcoxyle ayant de 1 à 6 atomes de carbone, phénoxy, amino et carboxy.


55

8. Composé selon les revendications 6 ou 7, caractérisé en ce que R^6 est choisi dans le groupe constitué par les groupes alkyle, cycloalkyle, alkyle substitué par un ou plusieurs groupes hydroxyle, ou cycloalkylalkyle substitué par un ou plusieurs groupes hydroxyle.

9. Composé selon les revendications 6, 7 ou 8, caractérisé en ce que R^7 est l'hydrogène.

10. Procédé de préparation d'un composé selon les revendications 1, 2, 3, 4, 5, 6, 7, 8 ou 9 possédant la structure

60




65



0 037 082


qui comprend les étapes de traitement de:

5



10. avec:


15



dans lequel M est un cation métallique, pour donner:

20

25




30

suivi d'un traitement; en présence d'une base, avec un agent d'alkylation ou d'acylation connu calculé pour mettre en place R⁶ et R⁷.

35

11. Procédé de préparation d'un composé selon les revendications 1, 2, 3, 4, 5, 6, 7, 8 ou 9 possédant la structure:

40




45

comprenant le traitement d'un composé selon la revendication 10 avec un acide de Lewis.

50

12. Procédé de préparation de:

55













60

65 comprenant l'étape de traitement d'un composé selon la revendication 11 avec un agent oxydant connu.




0037082

13. Composé selon la revendication 1 ou 2, caractérisé en ce que R' est l'hydrogène et R⁶ est choisi dans le groupe constitué par:



14. Procédé de préparation de



60 et de ses dérivés sels, esters et amides pharmaceutiquement acceptables, dans lesquels: R⁸ est choisi parmi l'hydrogène, les groupes substitués ou non substitués: alkyle, alcényle et alcynyle ayant de 1 à 10 atomes de carbone; cycloalkyle, cycloalkylalkyle et alkylcycloalkyle ayant 3 à 6 atomes de carbone dans le cycle cycloalkyle et 1 à 6 atomes de carbone dans les restes alkyle; phényle; arylalkyle, arylalcényle et arylalcynyle dans lesquels le reste aryle est le phényle et la partie aliphatique possède 1 à 6 atomes de carbone;

8A



0037082

hétéroaryle, hétéroarylalkyle, hétérocyclyle et hétérocyclylalkyle dans lesquels le reste hétéroaryle ou le reste hétérocyclyle possède 5 ou 6 chaînons contenant 1 à 4 atomes de O, N et S; dans laquelle le ou les substituants relatifs aux radicaux mentionnés ci-dessus sont choisis dans le groupe constitué par:

5

-X° halogéno (chloro, bromo, fluoro)

-OH ,

10

-OR¹ ,

$\begin{array}{c} \text{O} \\ \parallel \\ -\text{OCNR}^1\text{R}^2 \end{array}$,

15

$\begin{array}{c} \text{O} \\ \parallel \\ -\text{CNR}^1\text{R}^2 \end{array}$,

-NR¹R² ,

20

-NH₂ ,

-NHR¹ ,

25

$\begin{array}{c} \text{NR}^1 \\ \diagup \\ \text{NR}^1\text{R}^2 \end{array}$

-SO₂NR¹R² ,

30

$\begin{array}{c} \text{O} \\ \parallel \\ -\text{NHCNR}^1\text{R}^2 \end{array}$,

35

$\begin{array}{c} \text{O} \\ \parallel \\ -\text{R}^2\text{NCR}^1 \end{array}$,

-CO₂H ,

40

-CO₂R¹ ,

$\begin{array}{c} \text{O} \\ \parallel \\ -\text{CR}^1 \end{array}$,

45

$\begin{array}{c} \text{O} \\ \parallel \\ -\text{OCR}^1 \end{array}$,

50

-SH ,

$\begin{array}{c} \text{O} \\ \parallel \\ -\text{SR}^1 \end{array}$,

55

$\begin{array}{c} \text{O} \\ \parallel \\ -\text{SR}^1 \\ \parallel \\ \text{O} \end{array}$,

60

-CN ,



-N₃

dans lesquels les groupes R¹ et R² sont choisis indépendamment parmi: l'hydrogène, les groupes alkyle, alcényle et alcynyle ayant de 1 à 10 atomes de carbone; cycloalkyle, cycloalkylalkyle et alkylcycloalkyle




0 037 082


ayant 3 à 6 atomes de carbone dans le cycle cycloalkyle et 1 à 6 atomes de carbone dans les restes alkyle; phényle; arylalkyle, arylalcényle et arylalcynyle dans lesquels le reste aryle est le phényle et la partie aliphatique possède 1 à 6 atomes de carbone; hétéroaryle, hétéroarylalkyle, hétérocyclyle et hétérocyclylalkyle dans lesquels le reste hétéroaryle ou le reste hétérocyclyle possède 5 ou 6 chaînons contenant 1 à 4 atomes choises indépendamment parmi l'oxygène, l'azote ou le soufre et dans lesquels les restes alkyle associés auxdits restes hétérocycliques possèdent 1 à 6 atomes de carbone; ou dans lesquels R⁸ est le groupe $-(CH_2)_nX(CH_2)_mR^9$ dans lequel $n=2$ à 4, $m=2$ à 4, $X=NR^0$, O ou S; dans lequel R⁰ est H, CH₃, CH₂CH₃, CH₂CH₂OH ou CH₂CH₂NH₂ et R⁹ est OH, NH₂, NHCH₃, N(CH₂)₂,




lequel procédé comprend les étapes d'oxydation de:



pour former



dans lequel R^{1'} est l'hydrogène ou un groupe protecteur connu; et R⁰ est choisi indépendamment parmi les groupes alkyle ayant 1 à 6 atomes de carbone et phényle; suivie d'un traitement avec la 1,1'-carbonylimidazole puis avec (R^{2'}O₂CCH₂CO₂)₂Mg pour donner



dans lequel R^{2'} est un groupe protecteur connu ou un reste ester pharmaceutiquement acceptable; suivi d'une diazotation, cyclisation, activation et réaction avec HSR⁸.